

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|--|-----------|---|
| <p>(51) International Patent Classification ⁷ : C12N 15/53, 15/85, 15/11, 9/02, C12Q 1/02, C07K 16/40, A61K 39/395, 38/44, A01K 67/027, G01N 33/50, 33/53</p> | <p>A1</p> | <p>(11) International Publication Number: WO 00/53770 (43) International Publication Date: 14 September 2000 (14.09.00)</p> |
| <p>(21) International Application Number: PCT/EP00/01979 (22) International Filing Date: 7 March 2000 (07.03.00) (30) Priority Data: 99104664.0 9 March 1999 (09.03.99) EP (71) Applicant (for all designated States except US): MULTIGENE BIOTECH GMBH [DE/DE]; Biozentrum, Am Hubland, D-97074 Würzburg (DE). (72) Inventors; and (75) Inventors/Applicants (for US only): WEBER, Bernhard, H., F. [DE/DE]; Elsa-Brandström-Strasse 6, D-97218 Gerbrunn (DE). MARQUARDT, Andreas [DE/DE]; Zehntweg 16, D-97218 Gerbrunn (DE). (74) Agent: SCHMIDT, Werner; Robert-Bunsen-Strasse 15, D-65929 Frankfurt am Main (DE).</p> | | <p>(81) Designated States: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p> |
| <p>(54) Title: cDNA MOLECULES OF THE MEMBERS OF GENE FAMILY ENCODING HUMAN FATTY ACID DESATURASES AND THEIR USE IN DIAGNOSIS AND THERAPY</p> <div data-bbox="511 1186 1015 1627"></div> <p>(57) Abstract</p> <p>The present invention relates to the cloning and sequencing of the cDNA molecules of three members of a gene family encoding three human fatty acid desaturases, fatty acid desaturase-1 (FADS1), fatty acid desaturase-2 (FADS2) and fatty acid desaturase-3 (FADS3). The invention also relates to diagnostic methods of screening for and detection of FADS1, FADS2, FADS3 and gene therapy utilizing recombinant DNA as well as the generation of animal models (knock-in, knock-out, transgenic animals), anti-FADS1, anti-FADS2, anti-FADS3 antibodies and use in screenings for modulating drugs.</p> | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | ML | Mali | TR | Turkey |
| BG | Bulgaria | HU | Hungary | MN | Mongolia | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MR | Mauritania | UA | Ukraine |
| BR | Brazil | IL | Israel | MW | Malawi | UG | Uganda |
| BY | Belarus | IS | Iceland | MX | Mexico | US | United States of America |
| CA | Canada | IT | Italy | NE | Niger | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NL | Netherlands | VN | Viet Nam |
| CG | Congo | KE | Kenya | NO | Norway | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NZ | New Zealand | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | PL | Poland | | |
| CM | Cameroon | KR | Republic of Korea | PT | Portugal | | |
| CN | China | KZ | Kazakhstan | RO | Romania | | |
| CU | Cuba | LC | Saint Lucia | RU | Russian Federation | | |
| CZ | Czech Republic | LJ | Liechtenstein | SD | Sudan | | |
| DE | Germany | LK | Sri Lanka | SE | Sweden | | |
| DK | Denmark | LR | Liberia | SG | Singapore | | |
| EE | Estonia | | | | | | |

cDNA molecules of the members of gene family encoding human fatty acid desaturases and their use in diagnosis and therapy

5

Description

Field of the invention

The present invention relates to the cloning and sequencing of the cDNA molecules of three members of a gene family encoding three human fatty acid desaturases, fatty acid desaturase-1 (FADS1), fatty acid desaturase-2 (FADS2) and fatty acid desaturase-3 (FADS3). The invention also relates to diagnostic methods of screening for and detection of FADS1, FADS2, FADS3 and gene therapy utilizing recombinant DNA as well as the generation of animal models (knock-in, knock-out, transgenic animals), anti-FADS1, anti-FADS2, anti-FADS3 antibodies and use in screenings for modulating drugs.

Background of the Invention

Cellular membranes are dynamic structures in which variable amounts of proteins are embedded in a lipid bilayer whose hydrophobic characteristics are largely due to fatty acid moieties of complex lipids (Singer and Nicolson 1972). The 'fluidity' of the membranes are achieved by incorporating unsaturated fatty acyl chains of varying lengths and varying degrees of unsaturation into the lipids (Stubbs and Smith 1984). In animals, some of the unsaturated fatty acids need to be supplied by the diet ('essential polyunsaturated fatty acids') but, in part, can also be synthesized de novo by oxidative desaturation (i.e. formation of double bonds) of saturated fatty acids of plant and animal origin. Polyunsaturated fatty acid formation requires acetyl-CoA dependent chain elongation and desaturation. Most mammalian tissues can modify acyl chains by introducing more than one double bond with the first one generally at the Δ -9 position between carbons C-9 and C-10. Subsequent double bonds may then be inserted at the Δ -4, Δ -5, and Δ -6 positions by individual desaturase activities (Cook 1991).

For the two major precursors of the (n-6) and (n-3) series of polyunsaturated fatty acids, linoleic 18:2(n-6) and alpha-linolenic 18:3(n-3) acids, animals depend entirely on their dietary intake. By alternating sequences of desaturation (involving

the subsequent action of $\Delta 4$, $\Delta 5$ - and $\Delta 6$ -desaturases, respectively) and C2 chain elongation, linoleic and alpha-linolenic acids are utilized to form arachidonic acid, 20:4(n-6), and the (n-3) acyl chains eicosapentaenoic acid, 20:5(n-3), and docosahexaenoic acid, 22:6(n-3), respectively (Cook 1991).

5

- Linoleic and arachidonic acid are the only members of the (n-6) family that accumulate in large quantities in liver and most other animal tissues. The intermediates 18:3(n-6) and 20:3(n-6) are formed from 18:2(n-6) by $\Delta 6$ -desaturation, chain elongation and $\Delta 5$ -desaturation (Horrobin 1993). As a
- 10 component of phospholipids arachidonic acid is abundant in cellular membranes but also serves as the primary precursor of oxygenated derivatives such as prostaglandine E2 which is pro-inflammatory and regulates cell function of the immune system.
- 15 The (n-3) acyl chains eicosapentaenoic acid [20:5(n-3)] and docosahexaenoic acid [22:6(n-3)] are most abundant in cerebral cortex, retina, and spermatozoa. Although it is generally assumed that the liver is the major source of 22:6(n-3), it has been shown that docosahexaenoic acid can also be produced by retinal pigment epithelium (Wang and Anderson 1993) as well as brain astrocytes (Moore
- 20 et al. 1991, Delton-Vandenbrouke et al. 1997). In retinal rod outer segments, phospholipids may contain 40-60% of 22:6(n-3) which can markedly influence membrane fluidity due to the presence of six double bonds.

- In recent years there has been increasing interest in the role of polyunsaturated
- 25 fatty acids in the pathobiology of a number of chronic conditions such as coronary and peripheral vascular disease (Horrobin 1995), acute and chronic inflammatory immune responses (Calder 1998, Fan and Chapkin 1998, Grimble and Tappia 1998), cutaneous abnormalities (Horrobin 1989, Grattan et al. 1990), essential hypertension (Russo et al. 1997, Chi and Gupta 1998), diabetes mellitus (Mori et
- 30 al. 1997), asthma (Leichsenring et al. 1995, Villani et al. 1998, Hodge et al. 1998) and rheumatoid arthritis (James and Cleland 1997, Ariza-Ariza et al. 1998, Grimble and Tappia 1998). A particular role has been attributed to gamma-linolenic acid [18:3(n-6)] as an anti-cancer polyunsaturated fatty acid. It has been

shown that 18:3(n-6) confers anticancer properties by a variety of mechanisms such as (i) up-regulation of E-cadherin, a cell-cell adhesion molecule which acts as a suppressor of metastasis (Jiang et al. 1995), (ii) regulation of desmosome-mediated cell-cell adhesion in human cancer cells (Jiang et al. 1997a), (iii) up-regulation of the metastasis-suppressor gene nm-23 thus contributing to the inhibition of the in vitro invasion of tumor cells (Jiang et al. 1998a), (iv) up-regulation of maspin expression, a mammary serine protease inhibitor, with profound effects on motility of cancer cells (Jiang et al. 1997b) and (v) finally inhibition of cell cycle progression via regulation of phosphorylation and subsequent degradation of cell cycle inhibitors p27kip1 and p57kip2 (Jiang et al. 1998b).

To further understand lipid-related function in human health and disease additional research into fatty acid biosynthesis and metabolism is required. In particular, we need to understand the pharmacological properties, the mechanisms of action and the tissue-specific regulation of composition of the polyunsaturated fatty acids and their metabolites. This will provide additional insight into the role of the polyunsaturated fatty acids in various chronic disease states and will make it feasible to focus pharmacogenomic research on drug design and evaluation with the goal of ameliorating acute health problems associated with impaired lipid function. As a prerequisite, the genes and their gene products involved in the above-mentioned processes need to be identified and characterized.

It is the objective of the present invention to provide cDNA molecules of three novel members of the human membrane fatty acid desaturase gene family, termed FADS1, FADS2 and FADS3. The three genes share a nucleic acid identity of approximately 50-60% and an amino acid identity of about 77% with each other. Similar to other membrane-bound desaturases from mammals, fungi, insects, plants and cyanobacteria FADS1, FADS2 and FADS3 reveal a hydropathy profile typical of membrane-bound desaturases and share three regions of highly conserved primary sequence of the general histidine motif $HX_{2(3)}[XH]H$ (Shanklin et al. 1994). The histidine residues may act as metal-chelating ligands involved in the binding of oxygen in the reaction center (Shanklin et al. 1995). Together, these

features confirm FADS1, FADS2 and FADS3 as novel members of the desaturase family of fatty acyl chain-modifying enzymes.

Amino acid identity of FADS1, FADS2 and FADS3 to known desaturases (e.g. from *Arabidopsis thaliana*, *Brassica napus*, *Synechocystis spec.*, *Borago officinalis*, *Helianthus annuus*, *Saccharomyces cerevisiae* and *Caenorhabditis elegans*) is restricted to the respective carboxy terminal regions (amino acid positions 260 to 422) revealing an overall sequence identity of approximately 27%. Interestingly, the respective amino-termini of the three novel proteins demonstrate similarities to cytochrome b5 (amino acid positions 4 to 75; Fig. 1). Cytochrome b5 is a small hemoprotein and functions as an intermediate donor in a number of oxidation/reduction reactions including e.g. the NADH-dependent Δ^9 stearyl-CoA desaturation (Strittmatter et al. 1974) or the Δ^5 desaturation in cholesterol biosynthesis (Reddy et al. 1977). From the amino acid alignments we conclude that FADS1, FADS2 and FADS3 are fusion proteins consisting of a N-terminal cytochrome b5 and a C-terminal desaturase-like enzyme. From a functional point of view, this fusion of two activities may increase the efficiency of electron transport required for desaturation by covalently bringing together the presumed electron donor (cytochrome b5) and its putative acceptor (desaturase-like enzyme). Other heme fusion proteins containing the cytochrome b5 domain have been identified and represent a superfamily of fused proteins (Guiard and Lederer 1979). Besides others this superfamily includes the yeast flavocytochrome b₂, sulfite oxidase, nitrate reductase, the yeast Δ^9 acyl-CoA desaturase and more recently the sunflower cytochrome b5-desaturase fusion protein (Sperling et al. 1995). The three novel desaturase-like enzymes reported herein, FADS1, FADS2 and FADS3, can be added to the growing list of members of this superfamily of fused proteins (Fig. 2).

Summary of the invention

The eukaryotic fatty acid desaturases represent a group of iron-containing enzymes that catalyze NAD(P)H- and O₂-dependent introduction of double bonds into fatty acyl chains. Impairment of desaturase activities has been implicated in a variety of human conditions including liver disease, coronary artery disease and

cancer. With the present invention we are providing three isolated human cDNA molecules that encode three novel members of a cytochrome-b5-containing fusion protein with similarity to plant and lower animal desaturase enzymes, termed fatty acid desaturase-1 (FADS1) (represented by Fig. 3 and SEQ ID NO. 1), fatty acid
5 desaturase-2 (FADS2) (represented by Fig. 4 and SEQ ID NO. 2) and fatty acid desaturase-3 (FADS3) (represented by Fig. 5 and SEQ ID NO. 3).

FADS1 protein

MAPDPVAAETAAQGTPRYFTWDEVAQRSGCEERWLVIDRKVYNISEFTRRHP
10 GGSRVISHYAGQDATDPFVAFHINKGLVKYMNSELLIGELSPEQPSFEPTKNKEL
TDEFREL RATVERMGLMKANHVFLLYLLHILLDGAAWLTLWWFGTSFLPFLLC A
VLLSAVQAQAGWLQHDFGHLSVFSTSKWNHLLHHFVIGHLKGAPASWWNHMHF
QHHAKPNCFRKDPDINMHPFFALGKILSVELGKQKKKYPYNHQHKYFFLIGPP
ALLPLYFQWYIFYFVIQRKKWVDLAWMITFYVRFFLTYPVLLGLKAFLGLFFIVRFL
15 ESNWFVWWTQMNHHPMHIDHNRNMDWVSTQLQATCNVHKSANFDFSGHLNLF
QIEHHLFPTMPRHNYHKVAPLVQSLCAKHGIEYQSKPLLSAFADIIHSLKESGQLW
LDAYLHQ

FADS2 protein

20 MGKGGNQGEAAEREVSPTFSWEEIQKHNLRTDRWLVIDRKVYNITKWSIQHP
GGQRVIGHYAGEDATDAFRAFHDPLEFVGKFLKPLLIGELAPEEPSQDHGKNSKI
TEDFRALRKTAEDMNLFKTNHVFFLLLAHIIALESIAWFTVFYFGNGWIPTLITAFV
LATSQAQAGWLQHDYGHLSVYRKPKWNHLVHKFVIGHLKGASANWWNHRHFQ
HHAKPNIFHKDPDVNMLHVFLGEWQPIEYGKKKLKYPYNHQHEYFFLIGPPLLI
25 PMYFQYQIIMTMIVHKNWVDLAWAVSYIRFFITYIPFYGILGALLFLNFIRFLESHW
FVWWTQMNHIVMEIDQEAYRDWFSSQLTATCNVEQSFFNDWFSGHLNLFQIEHHL
FPTMPRHNHKLAPLVKSLCAKHGIEYQEKPLLRALLDIIRSLKKSGKLWLDAYLHK

FADS3 protein

30 MGGVGEPGPREGPAQPGAPLPTFCWEQIRAHQDQPGDKWLVIERRVYDISRWA
QRHPGGSRLIGHHGAEDATDAFRAFHQDLNFVRKFLQPLLIGELAPEEPSQDGP
LNAQLVEDFRALHQAEDMKLFDASPTFFAFLGHILAMEVLAWLLIYLLGPGWW
PSALAAFILAISQAQSWCLQHDLGHASIFKKSWWNHVAQKFVMGQLKGFSAHW

WNFRHFQHHAKPNIFHKDPDVTVAPVFLGESSVEYGKKKRRYLPYNQQHLYFF
LIGPPLLTLVNFEVENLAYMLVCMQWADLLWAASFYARFFLSYLPFYGVPGVLLF
FVAVRVLESHWFVWITQMNHIPKEIGHEKHRDWVSSQLAATCNVEPSLFTNWFS
GHLNFQIEHHLFPRMPRHNYSRVAPLVKSLCAKHGLSYEVKPFLTALVDIVRSLK
5 KSGDIWLDAYLHQ

Studies to clarify the specificity and the subcellular location of these ubiquitously expressed fusion proteins are in progress. Also, the detailed cellular functions and dysfunctions of the desaturase-like domains are being investigated in appropriate cellular and animal systems. This will address the question whether and to which extent these novel enzymes are involved in human disease. The invention encompasses the three cDNA molecules, FADS1, FADS2, and FADS3, the nucleotide sequence of these cDNAs, and the putative amino acid sequences of the FADS1 (represented by Fig. 6 and SEQ ID NO. 4), FADS2 (represented by Fig. 7 and SEQ ID NO. 5), and FADS3 represented by Fig. 8 and SEQ ID NO. 6) proteins.

Also comprehended by this invention are oligonucleotide primers comprising the cDNA molecule or its complementary strand allowing the amplification of FADS1 (represented by Fig. 9 and SEQ ID NOS. 7-12), FADS2 (represented by Fig. 9 and SEQ ID NOS. 13-18), and FADS3 (represented by Fig. 9 and SEQ ID NOS. 19-22), by the reverse transcriptase polymerase chain reaction (RT-PCR). Such primers are particularly useful and will provide researchers and physicians with an enhanced ability to assess the role of FADS1, FADS2, and FADS3 in human disease. The present invention also relates to methods of screening for and detection of FADS1, FADS2, and FADS3 mutation carriers including prenatal FADS1, FADS2, and FADS3 screening and diagnosis.

Having provided the isolated human FADS1, FADS2, and FADS3 cDNA sequences, also comprehended by this invention are the FADS1, FADS2, and FADS3 proteins, and derivatives thereof, in aspects of diagnosis and treatment of human disease. Finally, the invention pertains to proteins which comprise the same or substantially the same amino acid sequence (at least 200 amino acids) as

that represented by Figs. 6, 7, 8 and SEQ ID NOS. 4, 5, 6 or a variant of the amino acid sequences having a deletion, addition or substitution of 1 to 10 amino acids, or its salt.

- 5 Another aspect of the invention is the use of the FADS1, FADS2, and FADS3 proteins as a target for drug and gene therapy in the treatment of human disease. This includes the generation and utilization of FADS1, FADS2, and FADS3-targeted animal models (knock-in, knock-out, transgenic animals) and anti-FADS1, -FADS2, and -FADS3 antibodies that specifically detect the FADS1, FADS2, and
10 FADS3 proteins, respectively.

The foregoing and other features and advantages of the invention will become more apparent from the following detailed description and accompanying drawings.

15

One aspect of the invention are the isolated cDNAs selected from the group consisting of:

- (a) a polynucleotide having at least a 65 % homology, preferably at least a 80 % homology with a polynucleotide encoding a polypeptide selected
20 from the group consisting of the polypeptides of SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6;
- (b) a polynucleotide having at least a 65 % homology, preferably at least a 80 % homology with a polynucleotide which by virtue of the redundancy of the genetic code, encodes the same polypeptide selected from the
25 group consisting of the polypeptides of SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6;
- (c) a DNA molecule capable of hybridization under stringent conditions to a DNA molecule according to (a) or (b);
- (d) a polynucleotide which is complementary to the polynucleotide of (a), (b)
30 or (c); and
- (e) a oligonucleotide comprising at least 15 consecutive nucleotides of the polynucleotide of (a), (b), (c) or (d)

(including DNAs which are synonymous to the DNAs of (a), (b), (c), (d) and (e) due to the degeneracy of the genetic code)

especially isolated cDNAs selected from the group consisting of:

- 5 (a) a polynucleotide having at least a 65 % homology, preferably at least a 80 % homology with a polynucleotide sequence selected from the group consisting of the polynucleotides of SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3;
- (b) a DNA molecule capable of hybridization under stringent conditions to a
10 DNA molecule according to (a);
- (c) a polynucleotide which is complementary to the polynucleotide of (a) or (b);
- (d) an oligonucleotide comprising at least 15 consecutive nucleotides of the polynucleotide of (a), (b) or (c); and
- 15 (e) a DNA which is synonymous to the DNAs of (a), (b), (c) or (d) due to the degeneracy of the genetic code.

In the scope of the invention are polynucleotides having a polynucleotide encoding a polypeptide selected from the group consisting of the polypeptides of SEQ ID
20 NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3 and polynucleotides having a polynucleotide sequence selected from the group consisting of the polynucleotides of SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6, but DNAs comprising a nucleotide sequence with at least a 65 % homology with these nucleotide sequences is also within the scope of the invention.

25

Furthermore within the scope of the invention are:

A recombinant vector comprising the disclosed DNA molecules.

30 Transgenic host cells such as COS7, fibroblast cell lines or any other tissue-specific cell lines, as well as a transgenic host cell transformed by the DNA or the vector, a corresponding transgenic organism or a corresponding transgenic knock-in or knock-out animal model.

Polypeptides and corresponding proteins comprising at least 65 %, preferably 85 %, especially 100 % of a polypeptide sequence selected from the group consisting of the polypeptides of SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3; polypeptides comprising a polypeptide sequence with at least a 65 % homology
5 with the said polypeptides; peptides comprising at least 15, preferably 30, especially 60 consecutive amino acids of the said polypeptides; and polypeptides having substantially the same amino acid sequence as the said polypeptides, or having a variant of the amino acid sequence of the polypeptides with a deletion, addition or substitution of 1 to 10 amino acids. The salts of the peptides and
10 proteins are also within the scope of the invention.

A process for preparing the proteins which comprises cultivating the transformants to form the proteins.

15 A method of screening for modulators in well known assays using constructs such as FADS1, FADS2, and FADS3 promoter luciferase or green fluorescent protein hybrids or screening for interacting proteins or factors using state of the art technologies like the interaction trap technology to screen for interacting substances of FADS1, FADS2, and FADS3 or isolated domains of FADS1,
20 FADS2, and FADS3.

A method of screening chemical libraries comprising transformed cell lines

A compound which alters / reacts with at least one epitope of the proteins and
25 which is obtained by screening methods utilizing the FADS1, FADS2, and FADS3 cDNAs or protein molecules.

Use of antibodies against the FADS1, FADS2, and FADS3 proteins for diagnostic or therapeutic purposes.

30

A pharmaceutical composition comprising as an effective component of the proteins or a partial peptide of the proteins, and a pharmaceutically acceptable carrier or diluent.

The term "knock-out animal" as used herein is intended to describe an animal containing a gene which has been modified by homologous recombination. The homologous recombination event may completely disrupt the gene such that a functional gene product can no longer be produced (hence the name "knock-out")
5 or the homologous recombination event may modify the gene such that an altered, although still functional, gene product is produced.

The term "knock-in" as used herein is intended to describe a variation of gene targeting that uses homologous recombination but allows expression of added
10 genetic sequences in place of the endogenous gene. This approach allows the test of more subtle mutations than is allowed by a simple knock-out.

The term "epitope" describes a region on a macromolecule which is recognized by an antibody. Frequently it is in a short region of primary sequence in a protein and
15 it is generally about 5 to 12 amino acids long (the size of the antigen binding site on an antibody). Carbohydrates, nucleic acids and other macromolecules may be antigens and have epitopes.

20 Detailed Description of the Invention

Materials and Methods

Isolation of the FADS1 and FADS2 cDNAs

25 cDNA fragments corresponding to FADS1 and FADS2 were identified by direct cDNA selection. The cDNA selection was performed essentially as described (Rommens et al. 1993) with only minor modifications. Briefly, total RNA was prepared from human retina and from established human retinal pigment epithelium cell line ARPE-19 (Dunn et al. 1996). Prior to the use as templates for
30 cDNA synthesis the isolated RNAs were separated on a 1.2% agarose gel in the presence of 3-(N-morpholino)propanesulfonic acid (MOPS) and formaldehyde to check their integrity (Sambrook et al., 1989).

- RNAs were reverse transcribed using the SUPERScript™ preamplification system for first strand cDNA synthesis (Gibco, BRL) and the RXGT₁₂ oligonucleotide primer (5'-CGG AAT TCT CGA GAT CTT TTT TTT TTT TT-3'). After poly(A)-tailing with terminal transferase (United States Biochemical, USB), a
- 5 cDNA pool was generated by RXGT₁₂-primed PCR at 94°C for 1 min; 2 cycles of 94°C, 30 sec; 37°C, 1 min, 72°C, 2 min followed by 22 cycles of 94°C, 30 sec; 58°C, 30 sec and 72°C, 2 min. Prior to hybridization the cDNA pools were pre-annealed to C₆t-1 DNA (Gibco, BRL) enriched with sonicated LINE1 sequences.
- 10 Genomic PAC clones for cDNA selection were derived from 11q12-q13.1, a region known to contain the gene underlying Best's vitelliform macular dystrophy (Stöhr et al. 1998). The assembly and orientation of the clones have been described previously (Cooper et al. 1997). Inserts from PAC clones dJ465G21 and dJ139E20 (~1 µg) were isolated by NotI digestion, purified using QIAEXII agarose
- 15 gel extraction beads (Qiagen) and immobilized on Hybond-N+ membrane filters with an average concentration of 60 ng/mm². The insert filters were subjected to two consecutive rounds of hybridization with a starting mixture of 20 µg of retina and ARPE-19 derived cDNAs. Hybridization time was four days at 58°C in Church hybridization buffer (Church and Gilbert 1984). Filters were washed three times in
- 20 2 x SSC/0.1% SDS at room temperature, once each in 0.5 x SSC/0.1% SDS, 0.2 x SSC/0.1% SDS and 0.2 x SSC/0.05% SDS (all at 58°C). A final wash was in 2 x SSC. cDNAs were eluted in distilled H₂O by incubating for 10 min at 98°C and reamplified by PCR using the RXGT₁₂ oligonucleotide primer. Four µg of the reamplified cDNAs were used for a second round of hybridization. After two
- 25 rounds of selection the cDNAs were amplified using the RXGT₁₂ oligonucleotide primer, digested with EcoRI and cloned into the EcoRI site of pBluescript (Stratagene).
- The selected cDNAs represent segments of the 3'-untranslated region (3'-UTR) of
- 30 FADS1 (clone IVC4 at FADS1 nucleotide position 3793-4204; clone IVB7 at nucleotide position 3132-3609; clone VIIC6 at nucleotide position 2077-2317) (Fig. 3) and of the 3' UTR/coding sequence of FADS2 (clone IVB8 at FADS2 nucleotide position 2626-3009; clone TUK8-4B at nucleotide position 753-1508) (Fig. 4).

Using the selected clone sequences extensive dbEST database searches were conducted and revealed a large number of additional overlapping expressed sequence tags (ESTs). More than 100 ESTs (e.g. zk09h08, EST177650, yb28c03, ym29b05, yx67h05) were assembled to an overlapping EST contig representing

5 FADS1. The assembled EST sequences contain an open reading frame (ORF) of 1410 bp, with a first potential in-frame translation initiation codon, ATG, starting 79 nucleotides downstream the most 5'end of EST clone zk09h08.r1 (GenBank acc. no. AA029030) (Fig. 1a). A consensus polyadenylation signal, AAUAAA, was identified at nucleotide position 4.182. The mature protein predicted from the ORF

10 consists of 444 amino acid residues resulting in a calculated molecular mass of 52.0 kDa (Fig. 6).

Another 30 overlapping ESTs (e.g. cp2485.seq, HSC2EA121, EST06759, ym42c04, nc08c05) were found facilitating the assembly of the FADS2 cDNA. The

15 assembled EST sequences contain an open reading frame (ORF) of 1352 bp, with a first potential in-frame translation initiation codon, ATG, starting 21 nucleotides downstream the most 5'end of EST clone ub64e01.r1 (GenBank acc. no. AI036465) (Fig. 4). Consensus polyadenylation signals were predicted at nucleotide positions 2.996 and 4.056. The mature FADS2 protein predicted from

20 the ORF consists of 444 amino acid residues resulting in a calculated molecular mass of 52.3 kDa (Fig. 7). Amino acid sequence identity between FADS1 and FADS2 is 62%.

Isolation of the FADS3 cDNA

25 Additional 30 human EST clones were available to assemble a third individual cDNA, termed FADS3 (e.g. zs84e06, zs84e05, nq23f05, ya49a19, zs86h09). The existence of a third member of the FADS family was confirmed by PCR mapping of FADS1-, FADS2- and FADS3-specific 3'-UTR fragments revealing three distinct gene loci within a 1.4 Mb PAC contig in 11q12-q13.1 (Cooper et al., 1997). The

30 assembled EST sequences contain an open reading frame (ORF) of 1468 bp, with a first potential in-frame translation initiation codon, ATG, starting 134 nucleotides downstream the most 5'end of EST clone qa99d06.s1 (GenBank acc. no. AI123992) (Fig. 5). The mature protein predicted from the ORF consists of 445

amino acid residues resulting in a calculated molecular mass of 51.2 kDa (Fig. 8). The 3'-UTR of the FADS3 cDNA is represented by several EST clones (e.g. zs86h09.s1, AA279632). A potential polyadenylation signal, AUUAAA, is present at cDNA nucleotide position 1.757 and may be functional as AUUAAA is the most
5 common natural variant of the consensus polyadenylation signal AAUAAA (Fig. 5) (Sheets et al., 1990).

Amino acid sequence identities between FADS1 and FADS3 as well as between FADS2 and FADS3 are 52% and 63%, respectively. All EST sequences in the
10 dbEST databases could be aligned to one of the three cDNAs, FADS1, FADS2, and FADS3. This suggests that there are no additional members of the FADS family in the human genome.

Northern blot analysis

15 Northern blot analysis was performed either with total RNA isolated using the guanidinium thiocyanate method (Chomczynski and Sacchi 1987) or with commercially available multiple tissue Northern (MTN) blots purchased from Clontech Laboratories Inc. (Palo Alto, CA). Each lane of the total RNA blot contained 12 µg of total RNA from lung, cerebellum, uterus, retina, liver, heart,
20 RPE cell line ARPE-19, RPE tissue, lymphocytes and was electrophoretically separated in the presence of formaldehyde. The MTN blots were prepared from poly(A)⁺ RNA isolated from human heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas. Inserts of clones IVC4, IVB7 (FADS1), IVB8 (FADS2) and of the 362 bp PCR product F3/R (5'-ACAGCTTTCCCCCAATTCTC-
25 3'/5'-GGCCTCAGCTACGAAGTGAAG-3') (FADS3) derived from the 3'-UTRs of the respective genes were used for filter hybridization at 65°C in 0.5 mM sodium phosphate buffer, pH 7.2; 7% SDS, 1 mM EDTA at 65°C (Church and Gilbert 1984).

30 The three genes are ubiquitously expressed and appear to have similar expression levels in all tissues analyzed. FADS1 revealed a transcript size of 4.0 kb while FADS2 revealed a similar sized transcript of 4.0 kb in addition to a smaller transcript of approximately 3.1 kb. The two FADS2 variants may be due to

differential usage of polyadenylation signals (see above). Finally, FADS3 is represented by two transcripts of 1.75 kb and 1.25 kb in size. While the former is in agreement with the usage of the variant polyadenylation signal identified at position 1738 of the cDNA, the small size of the latter transcript can not be explained at present and it does not appear to be due to a differential usage of polyadenylation signals. Possibly, differential splicing and/or exon skipping may be involved in the generation of the variant transcript. However, there is no evidence from cDNA cloning or EST contig assembly to support this possibility.

10 Comparison with other desaturases

Local sequence alignments of the deduced amino acid sequences of FADS1, FADS2, and FADS3 with known proteins or protein motifs were done using SwissProt (<http://www.ncbi.nlm.nih.gov/cgi-bin/Blast/nph-blast?Jform=0>) and the BLASTP and BEAUTY programs at Baylor College of Medicine (<http://dot.imgen.bcm.tmc.edu:9331/seq-search/protein-search.html>). Amino acid sequence alignments were performed using the CLUSTALW multiple alignment program at http://pbil.ibcp.fr/NPSA/npsa_clustalw.html. Phylogenetic tree assembly was done using the TREECON software Version 1.3b available at <http://bioc-www.uia.ac.be/u/yvdp/index.html>.

20

Overall amino acid identities to known desaturases were found to be in the range of 22% - 27% (Fig. 1). Phylogenetic tree construction revealed a genetic relationship of FADS1, FADS2, and FADS3 to the $\Delta 5$ -, $\Delta 6$ - and $\Delta 8$ -desaturases with some distance to the $\Delta 9$ -desaturases (Fig. 2). From these analyses it becomes obvious that sequence identity by itself is not a predictor of a specific desaturase activity. For example, $\Delta 5$ - and $\Delta 6$ -desaturases from *C. elegans* demonstrate a higher sequence identity to each other than to the $\Delta 6$ -desaturases from other species. We therefore conclude that based on simple sequence comparisons it is not feasible to determine the specific functions of FADS1, FADS2, and FADS3. This will be done by transgene expression of the three desaturases combined with gas chromatography-mass spectrometry.

30

Hydropathy plots of FADS1, FADS2, and FADS3 indicate two hydrophobic sequences predicted to represent transmembrane-spanning domains similar to other desaturases identified thus far (Fig. 1) (reviewed in Sperling et al. 1995).

5 cDNA amplification of FADS1, FADS2, and FADS3

The coding sequences of the three genes are amplified in overlapping fragments by performing RT-PCR using oligonucleotide primer pairs derived from the respective cDNA sequences:

10 (1) FADS1 (Fig. 9 and SEQ ID NOS. 7-12)

Sense primer TU12-R5 (5'-CGCCTGACAGCCCCTGCT-3') at cDNA position 31-48 in combination with antisense primer TU12-F10 (5'-CAGGTGGCCAATCACAAAAT-3') at cDNA position 671-690 results in a product of 660 bp; sense primer TU12-R7 (5'-CTCAAAGTGGAACCATCTGCTA-3') at

- 15 cDNA position 645-666 in combination with antisense primer TU12-F9 (5'-GGAAACCCAGTCCATGTTCC-3') at cDNA position 1130-1149 results in a product of 505 bp; sense primer TU12-R6 (5'-CCTGGGCCTTTTCTTCATAGT-3') at cDNA position 1035-1055 in combination with antisense primer TU12-F5 (5'-CTCAAGCTCCCCTCTGCCT-3') at cDNA position 1465-1483 results in a product of 449 bp.

(2) FADS2 (Fig. 9 and SEQ ID NOS. 13-18)

Sense primer TU13-R4 (5'-TCAGAAGCATAACCTGCGC-3') at cDNA position 98-116 in combination with antisense primer TU13-F7 (5'-

- 25 CCAGTTCACCAATCAGCAGG-3') at cDNA position 284-303 results in a product of 206 bp; sense primer TU13-R3 (5'-CCCCTGCTGATTGGTGAAC-3') at cDNA position 282-301 in combination with antisense primer TU13-F4 (5'-TGTAGGGCAGGTATTCAGC-3') at cDNA position 779-798 results in a product of 517 bp; sense primer TU13-R2 (5'-AGCCCATCGAGTACGGCAA-3') at cDNA position 754-772 in combination with antisense primer TU13-F1 (5'-CCTCAGAACAAAAGCCCATC-3') at cDNA position 1416-1435 results in a product of 682 bp.

(3) FADS3 (Fig. 9 and SEQ ID NOS. 19-22)

Sense primer TU19-R2 (5'-TCTTGCTCGGACCTCGGC-3') at LLC DL3 cDNA

position 81-98 in combination with antisense primer TU19-F2 (5'-

GTGATCCACACGAACCAGTG-3') at cDNA position 1130-1149 position results in

- 5 a product of 1069 bp; sense primer TU19-R3 (5'-GAAGAACCCAGCCAGGATG-3')
at cDNA position 428-446 in combination with antisense primer TU19-F3 (5'-
ACAGCTTTCCCCCAATTCTC-3') at cDNA position 1709-1728 results in a product
of 1301 bp.

10 Short description of Figures

Fig. 1 Comparison of putative amino acid sequences from FADS1, FADS2,

FADS3, *Borago officinalis*, *Helianthus annuus* and human cytochrome b5.

Arrowheads indicate eight invariant amino acid residues typical for the cytochrome
b5 domain. Two potential transmembrane domains are boxed. Three histidine

- 15 motifs $HX_{2(3)}[XH]H$ that are conserved within the desaturase family are hatched.

Fig. 2 Phylogenetic tree of fatty acid desaturases.

Fig. 3 (SEQ ID NO. 1) shows the nucleotide sequence of the FADS1 cDNA

Fig. 4 (SEQ ID NO. 2) shows the nucleotide sequence of the FADS2 cDNA

Fig. 5 (SEQ ID NO. 3) shows the nucleotide sequence of the FADS33 cDNA

- 20 Fig. 6 (SEQ ID NO. 4) shows the putative amino acid sequence of the predicted
FADS1 protein

Fig. 7 (SEQ ID NO. 5) shows the putative amino acid sequence of the predicted
FADS2 protein

Fig. 8 (SEQ ID NO. 6) shows the putative amino acid sequence of the predicted

- 25 FADS3 protein

Fig. 9 (SEQ ID NOS. 7-22) shows the oligonucleotide PCR primers utilized to
amplify the FADS1, FADS2, FADS3 cDNA, respectively.

References

- Ariza-Ariza R, Mestanza-Peralta M, Cardiel MH. Omega-3 fatty acids in rheumatoid arthritis: an overview. *Semin Arthritis Rheum* 27: 366-370 (1998)
- Calder PC. Immunoregulatory and anti-inflammatory effects of n-3 polyunsaturated fatty acids. *Braz J Med Biol Res* 31: 467-490 (1998)
- Chi Y, Gupta RK. Alterations in membrane fatty acid unsaturation and chain length in hypertension as observed by ¹H NMR spectroscopy. *Am J Hypertens* 11: 340-348 (1998)
- Chomczynski, P. and Sacchi, N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. *Anal Biochem* 162: 156-159 (1987)
- Church, G.M., and W. Gilbert. Genomic sequencing. *Proc Natl Acad Sci USA* 81:1991-1995 (1984)
- Cook HW. Fatty acid desaturation and chain elongation in eucaryotes. In: *Biochemistry of lipids, lipoproteins and membranes*, Vance DE & Vance JE (eds), Elsevier Amsterdam London, New York, pp.141-169 (1991)
- Cooper P, Nowak NJ, Higgins MJ, Simpson SA, Stöhr H, Marquardt A, Weber BHF, Gerhard DS, deJong P, Shows TB. A sequence ready high resolution physical map of the Best's macular dystrophy gene region in 11q12-q13. *Genomics* 41: 185-192 (1997)
- Delton-Vandenbrouke I, Grammas P, Anderson RE. Polyunsaturated fatty acid metabolism in retinal and cerebral microvascular endothelial cells. *J Lipid Res* 38:147-159 (1997)
- Dunn KC, Aotaki-Keen AE, Putkey FR, Hjelmeland LM. ARPE-19, a human retinal pigment epithelial cell line with differentiated properties. *Exp Eye Res* 62: 155-169 (1996)
- Fan YY, Chapkin RS. Importance of dietary gamma-linolenic acid in human health and nutrition. *J Nutr* 128: 1411-1414 (1998)
- Grattan C, Burton JL, Manku M, Stewart C, Horrobin DF. Essential-fatty-acid metabolites in plasma phospholipids in patients with ichthyosis vulgaris, acne vulgaris and psoriasis. *Clin Exp Dermatol* 15: 174-176 (1990)

- Grimble RF, Tappia PS. Modulation of pro-inflammatory cytokine biology by unsaturated fatty acids. *Z Ernährungswiss* 37 (Suppl 1): 57-65 (1998)
- Guiard B, Lederer F. The "cytochrome b5 fold": structure of a novel protein superfamily. *J Mol Biol* 135: 639-50 (1979)
- 5 Hodge L, Salome CM, Hughes JM, Liu-Brennan D, Rimmer J, Allman M, Pang D, Armour C, Woolcock AJ. Effect of dietary intake of omega-3 and omega-6 fatty acids on severity of asthma in children. *Eur Respir J* 11: 361-536 (1998)
- Horrobin DF. Abnormal membrane concentrations of 20 and 22-carbon essential fatty acids: a common link between risk factors and coronary and peripheral
- 10 vascular disease? *Prostaglandins Leukot Essent Fatty Acids* 53: 385-396 (1995)
- Horrobin DF. Essential fatty acids in clinical dermatology. *J Am Acad Dermatol* 20: 1045-1053 (1989)
- Horrobin DF. Fatty acid metabolism in health and disease: the role of $\Delta 6$ -desaturase. *Am J Clin Nutr* 57(5 Suppl): 732S-737S (1993)
- 15 James MJ, Cleland LG. Dietary n-3 fatty acids and therapy for rheumatoid arthritis. *Semin Arthritis Rheum* 27: 85-97 (1997)
- Jiang WG, Bryce RP, Horrobin DF, Mansel RE. gamma-Linolenic acid blocks cell cycle progression by regulating phosphorylation of p27kip1 and p57kip2 and their interactions with other cycle regulators in cancer cells. *Int J Oncol* 13: 611-617
- 20 (1998b)
- Jiang WG, Hiscox S, Bryce RP, Horrobin DF, Mansel RE. The effects of n-6 polyunsaturated fatty acids on the expression of nm-23 in human cancer cells. *Br J Cancer* 77: 731-738 (1998a)
- Jiang WG, Hiscox S, Hallett MB, Horrobin DF, Mansel RE, Puntis MC. Regulation
- 25 of the expression of E-cadherin on human cancer cells by gamma-linolenic acid (GLA). *Cancer Res* 55: 5043-5048 (1995)
- Jiang WG, Hiscox S, Horrobin DF, Bryce RP, Mansel RE. Gamma linolenic acid regulates expression of maspin and the motility of cancer cells. *Biochem Biophys Res Commun* 237: 639-644 (1997b)
- 30 Jiang WG, Singhrao SK, Hiscox S, Hallett MB, Bryce RP, Horrobin DF, Puntis MC, Mansel RE. Regulation of desmosomal cell adhesion in human tumor cells by polyunsaturated fatty acids. *Clin Exp Metastasis* 15: 593-602 (1997a)

- Leichsenring M, Kochsiek U, Paul K. (n-6)-Fatty acids in plasma lipids of children with atopic bronchial asthma. *Pediatr Allergy Immunol* 6: 209-212 (1995)
- Moore SA, Yoder E, Murphy S, Dutton GR, Spector AA. Astrocytes, not neurons, produce docosahexaenoic acid (22:6 omega-3) and arachidonic acid (20:4 omega-6). *J Neurochem* 56: 518-524 (1991)
- Mori Y, Murakawa Y, Katoh S, Hata S, Yokoyama J, Tajima N, Ikeda Y, Nobukata H, Ishikawa T, Shibutani Y. Influence of highly purified eicosapentaenoic acid ethyl ester on insulin resistance in the Otsuka Long-Evans Tokushima Fatty rat, a model of spontaneous non-insulin-dependent diabetes mellitus. *Metabolism* 46: 1458-1464 (1997)
- Reddy VV, Kupfer D, Caspi E. Mechanism of C-5 double bond introduction in the biosynthesis of cholesterol by rat liver microsomes. *J Biol Chem* 252: 2797-2801 (1977)
- Rommens JM, Lin B, Hutchinson GB, Andrew SE, Goldberg YP, Glaves ML, Graham R, Lai V, McArthur J, Nasir J, Theilmann J, McDonald H, Kalchman M, Clarke LA, Schappert K, Hayden MR. A transcription map of the region containing the Huntington disease gene. *Hum Mol Genet* 2: 901-907 (1993)
- Russo C, Olivieri O, Girelli D, Guarini P, Pasqualini R, Azzini M, Corrocher R. Increased membrane ratios of metabolite to precursor fatty acid in essential hypertension. *Hypertension* 29: 1058-1063 (1997)
- Sambrook J, Fritsch EF, Maniatis T. *Molecular Cloning, A Laboratory Manual*, 2nd Edition, Cold Spring Harbor Laboratory Press, USA (1989)
- Shanklin J, Whittle E, Fox BG. Eight histidine residues are catalytically essential in a membrane-associated iron enzyme, stearoyl-CoA desaturase, and are conserved in alkane hydroxylase and xylene monooxygenase. *Biochem* 33: 12787-12794 (1994)
- Shanklin J, Whittle EJ, Fox BG. Membrane bound desaturases and hydroxylases: Structure function studies, in *Plant lipid metabolism*, Kader JC, Mazliak P (eds), Kluwer Academic Publishers, Netherlands, pp.18-20 (1995).
- Sheets MD, Ogg SC, Wickens MP. Point mutations in AAUAAA and the poly (A) addition site: effects on the accuracy and efficiency of cleavage and polyadenylation in vitro. *Nucl Acid Res* 18: 5799-5805 (1990)

- Singer SJ, Nicolson GL. The fluid mosaic model of the structure of cell membranes. *Science* 175: 720-731 (1972)
- Sperling P, Schmidt H, Heinz E. A cytochrome b5-containing fusion protein similar to plant acyl lipid desaturases. *Eur J Biochem* 232: 798-805 (1995)
- 5 Stöhr H, Marquardt A, Rivera A, Cooper PR, Nowak NJ, Shows TB, Gerhard DS, Weber BHF. A gene map of the Best's vitelliform macular dystrophy region in chromosome 11q12-q13.1. *Genome Res* 8: 48-56 (1998)
- Strittmatter P, Spatz L, Corcoran D, Rogers MJ, Setlow B, Redline R. Purification and properties of rat liver microsomal stearyl coenzyme A desaturase. *Proc Natl Acad Sci USA* 71: 4565-4569 (1974)
- 10 Stubbs CD, Smith AD. The modification of mammalian membrane polyunsaturated fatty acid composition in relation to membrane fluidity and function. *Biochim Biophys Acta* 779: 89-137 (1984)
- Villani F, Comazzi R, De Maria P, Galimberti M. Effect of dietary supplementation with polyunsaturated fatty acids on bronchial hyperreactivity in subjects with seasonal asthma. *Respiration* 65: 265-269 (1998)
- 15 Wang N, Anderson RE. Synthesis of docosahexaenoic acid by retina and retinal pigment epithelium. *Biochemistry* 32: 13703-13709 (1993)

3. A DNA comprising a nucleotide sequence with at least a 65 % homology with the nucleotide sequences as defined in claim 1 or 2.
4. A recombinant vector comprising the DNA as claimed in any of claims 1 to 3.
5. A transgenic host cell comprising the DNA as claimed in any of claims 1 to 3.
- 10 6. A transgenic host cell transformed by the DNA according to any of claims 1 to 3 or the vector according to claim 4, a corresponding transgenic organism or a corresponding transgenic knock-in or knock-out animal model.
- 15 7. A polypeptide comprising at least 65 % of a polypeptide sequence selected from the group consisting of the polypeptides of SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, or its salt.
- 20 8. A polypeptide comprising a polypeptide sequence with at least a 85 % homology with the polypeptide sequence as claimed in claim 7, or its salt.
9. A peptide comprising at least 15 consecutive amino acids of the polypeptide as claimed in claim 7, or its salt.
- 25 10. A polypeptide having substantially the same amino acid sequence as the polypeptide as claimed in claim 7, or having a variant of the amino acid sequence of the polypeptide as claimed in claim 7 with a deletion, addition or substitution of 1 to 10 amino acids, or its salt.
- 30 11. A process for producing a polypeptide comprising expressing from the host cell of claim 5 or 6 a polypeptide encoded by the DNA as claimed in any of claims 1 to 3.

Claims

1. An isolated cDNA molecule selected from the group consisting of:
- 5 (a) a polynucleotide having at least a 65 % homology, preferably at least a 80 % homology with a polynucleotide encoding a polypeptide selected from the group consisting of the polypeptides of SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6;
- 10 (b) a polynucleotide having at least a 65 % homology, preferably at least a 80 % homology with a polynucleotide which by virtue of the redundancy of the genetic code, encodes the same polypeptide selected from the group consisting of the polypeptides of SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6;
- a DNA molecule capable of hybridization under stringent conditions to a DNA molecule according to (a) or (b);
- 15 (c) a polynucleotide which is complementary to the polynucleotide of (a), (b) or (c); and
- (d) an oligonucleotide comprising at least 15 consecutive nucleotides of the polynucleotide of (a), (b), (c) or (d).
- 20 2. An isolated cDNA molecule selected from the group consisting of:
- (a) a polynucleotide having at least a 65 % homology, preferably at least a 80 % homology with a polynucleotide sequence selected from the group consisting of the polynucleotides of SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3;
- 25 (b) a DNA molecule capable of hybridization under stringent conditions to a DNA molecule according to (a);
- (c) a polynucleotide which is complementary to the polynucleotide of (a) or (b);
- 30 (d) an oligonucleotide comprising at least 15 consecutive nucleotides of the polynucleotide of (a), (b) or (c); and
- (e) a DNA which is synonymous to the DNAs of (a), (b), (c) or (d) due to the degeneracy of the genetic code.

12. An antibody against the polypeptide of any of claims 7 to 10.
13. A oligonucleotide primer having a nucleotide sequence selected from the group consisting of the nucleotide sequences of SEQ ID NO: 7 to SEQ ID NO: 22.
5
14. A method of screening for modulators in known assays using constructs or of screening for interacting proteins or factors using state of the art technologies.
10
15. A method of screening chemical libraries comprising transformed cell lines.
16. A compound which alters or reacts with at least one epitope of the proteins and which is obtained by screening methods as claimed in claim 14 or 15.
15
17. The use of the antibodies according to claim 12 for diagnostic or therapeutic purposes.
18. A pharmaceutical composition comprising as an effective component an effective amount of the peptide as claimed in any of claims 7 to 10, or its salt, and a pharmaceutically acceptable carrier or diluent.
20

| | | |
|---------------|-----|---|
| FADS1 | 1 | ..MAPDPVAAPTAAGGPTP..RYFTWDEVAQRSGCDEERWLVIDRKVYNI SEFTTRHPGGSR |
| FADS2 | 1 | MKGKCGNQC..EGAAEREVSVPTEFWEEI OKHNLRLRLWLVIDRKVYNI TKWSTCHPGGGR |
| FADS3 | 1 | MGGVGEPPGREGPAQPCAPLPTEFCWEQIRAHDOPCDKWLVIERRVYDI SRWAQRHPGGSR |
| Borago | 1 |MRAQIKKYITTSDELKNDKPCDLWIS..QCKAYDVSDWVKDHPGGSF |
| Helianthus | 1 |MVSPSIEVLNSIADGKMYITSKELKKHNNPNLWIS..LGKVYVWTEWAKEHPGGDA |
| Cytochrome b5 | 1 |MPEQSDAEVXYTLEEI OKHNHKSSTNLILHKKVYD..TKLELHPGGEE |
| FADS1 | 58 | VISHYAGQDATDPEFAFHINKGLVKKYMNSSLIGELISPEQPSSEPTKRELTEEFRELRA |
| FADS2 | 59 | VIGHYAGQDATDAFRAFHEDLEEVGKFLKLLIGELAPEEP SODHGKSKITEDFRALRK |
| FADS3 | 61 | LICHGAEADATDAFRAFHODLNVKRELQPLLIGELAPEEP SODGPLSAQI VEDFRALHQ |
| Borago | 47 | ELKSLAQGVTDADFVAFHEDLW...KNLDKFFTCYLLKQYV.....SEVSKDYRKLVF |
| Helianthus | 57 | ELINLAGQVTDADFIAFHEDLW...KHLDKLFTCYHLKQYV.....SDISRDYRKLAS |
| Cytochrome b5 | 50 | VIREQAGCATENEEDVGHSDA..REMSKTFILIGELHEDDR.....PKLNKPPETLIT |
| FADS1 | 118 | IVERMGLKANHVFLLIYLHLLLDGAANLTLWVFGTSFLLELLCAVLLSAVQACAGWL |
| FADS2 | 119 | IAEDYNLEKTNHVFLLLEAHLIALESIAWETVEYEGNGWIPLITAFVLATSOACAGWL |
| FADS3 | 121 | AAEDYNLEFASPTFEAFLLGHLAMEVLAMLLIYLCPGVVESALAFILATSOAGSWL |
| Borago | 99 | EFKCYGLYDKKCHIMFATLCHFLAMEVAMSVYGV..LFCEGVVHLESCOLMGCTLWIAQSWI |
| Helianthus | 109 | EFKAGMEKKGHGVLYSLCFVSLILLSACVYGV..LYSGSPWIHMLSCAILGLAWMCIAYL |
| Cytochrome b5 | 102 | TIDSSSSWWTNWIIPATSAVAVALMYRYMAED..... |
| FADS1 | 178 | QHDGSHLSVESTSKWNHLHFFVIGHLKCAPASWNNHMFQHHAKPNCEKDPDINMHPE |
| FADS2 | 179 | QHDYGHLSVYRKPKWNHLVHKFVIGHLKCAPASWNNHMFQHHAKPNIEHKDPDVMNHV |
| FADS3 | 181 | CHDGHASIEKNSWNNHVAQEVMGOLKGFSAHWNNERHFQHHAKPNIEHKDPDVTVAPE |
| Borago | 158 | CHDAGHMVVSDELNKEFGIFAAANCLSGISICGWKWNHNAHIIAONSLEYDPDLOYIPE |
| Helianthus | 168 | CHDAGHYQMATRGWKKFAGTIFGNCTICISLAWKWTENAHIIAONSLEYDPDLOHLPN |
| FADS1 | 238 | BEA....LGKILSYDLGKQ....KKKMPYNNHCHYFFFLIGPPLIPLYFCWLYIFYFVI. |
| FADS2 | 239 | FV.....LGWQPIEYCHN....KKKYLPPYNNHCHYFFFLIGPPLIPMYEQYQIIMTMH. |
| FADS3 | 241 | FL.....LCE..SSVEYCKK....KRYLPPYNNHCHYFFFLIGPPLIPLVNNEVENLAYMT. |
| Borago | 218 | LIVSSKFFGSLTSHFYEKRLTFDLSLRFFVSYQHWTFFP..MCAARINMYVQSLIMLLTKR |
| Helianthus | 228 | LAVSSKLFNSITSIFYGRQLTFDPLARFFVSYQHLYLPPFMCVARVNLVLTITLLISKR |
| FADS1 | 289 | .QRKKWVDLAW..ITFYVRFELTYVELLGLKAFGLLEFFIVRELESNWFVWVTQNNHIP..M |
| FADS2 | 289 | .VHKWVDLAWPVSYIIRFFITYIPFYCILGALLEINFIRESHWFVWVTQNNHIV..M |
| FADS3 | 290 | .VCMQADLLWASFFIARFFLSYLFYGVPCVILLFEVAVRVLESNWFVWVTQNNHIP..K |
| Borago | 278 | NVSYRABELLIGOLVESINWELVSCLENWGERIMEVIA SLVTCMQQVQFS..LNHFSSSV |
| Helianthus | 288 | KIPDRGLNILLGLIEFWTWELVSRLENWPERVAFVLVSFCVTGIGIQLIFT..LNHFSGCV |
| FADS1 | 346 | HIDHDMNDWVSTQLQATCNVHKSAENDWFSCHLNFEQIEHHLFPMPRNNHKKVAPLVQS |
| FADS2 | 346 | EIDQEAIRDWFSQLTATCNVEQSEFNWFSCHLNFEQIEHHLFPMPRNNHKKIAPLVKS |
| FADS3 | 347 | EIGHENHRDWVSSQLAATCNVEPSLEFNWFSCHLNFEQIEHHLFPMPRNNHKSRAVLVKS |
| Borago | 337 | YVCKPACNNWEEKTDGTLDISCPPAMDWETHCLOFQIEHHLFPMKIFRONLKKISPYVIE |
| Helianthus | 347 | YVCPKCDNWFEKOTRGTDIACSSAMDWETHCLOFQIEHHLFPMKIFRCHLRSISPIORE |
| FADS1 | 406 | LCAKHGIEYOSKEPLLSAFADIHSLKESGOLWLDAYLHQ..... |
| FADS2 | 406 | LCAKHGIEYOEKPLRLALDIIRSLKESGOLWLDAYLHK..... |
| FADS3 | 407 | LCAKHGLSYEVKPELTALVDIVRSIKKSGDEWLDAYLHQ..... |
| Borago | 397 | LCKKHNLPPNYASFSKANEMTLRTLRNTALQARDITKPLPKNLVWEALHTHG |
| Helianthus | 407 | LCKKHNLPPVSLSEYDENVTTEKTLRTAALQARDLTNPAPQNLAWFAFNTHG |

☐ transmembrane region

☐ conserved histidine box

▼ invariant amino acid residue

Fig. 1

Fig.2




Fig. 3

FADS1 cDNA

CACTCCTGGAGCCCCGCGGACCCCGAGCACGCGCCTGACAGCCCCCTGCTGGCCCCGGCGCGCGGGCG
TCGCCAGGCCAGCTATGGCCCCCGACCCGGTGGCCGCCGAGACCGCGGCTCAGGGACCTACCCC
GCGCTACTTCACCTGGGACGAGGTGGCCCCAGCGCTCAGGGTGCGAGGAGCGGTGGCTAGTGATC
GACCGTAAGGTGTACAACATCAGCGAGTTCACCCGCCGGCATCCAGGGGGCTCCCGGGTCATCA
GCCACTACGCCGGGCAGGATGCCACGGATCCCTTTGTGGCCTTCCACATCAACAAGGGCCTTGT
GAAGAAGTATATGAACTCTCTCCTGATTGGAGAAGTGTCTCCAGAGCAGCCAGCTTTGAGCCC
ACCAAGAATAAAGAGCTGACAGATGAGTTCGGGGAGCTGCGGGCCACAGTGGAGCGGATGGGGC
TCATGAAGGCCAACCATGTCTTCTTCTGCTGTACCTGCTGCACATCTTGCTGCTGGATGGTGC
AGCCTGGCTCACCCCTTTGGGTCTTTGGGACGTCCTTTTTGCCCTTCCCTCCTCTGTGCGGTGCTG
CTCAGTGCAGTTCAGGCCCAGGCTGGCTGGCTGCAGCATGACTTTGGGCACCTGTGCGGTCTTCA
GCACCTCAAAGTGGAACCATCTGCTACATCATTTTGTGATTGGCCACCTGAAGGGGGCCCCCGC
CAGTTGGTGGAACCATGCACTTCCAGCACCATGCCAAGCCCAACTGCTTCCGCAAAGACCCA
GACATCAACATGCACTCCCTTCTTCTTGGCTTGGGGAAGATCCTCTCTGTGGAGCTTGGGAAAC
AGAAGAAAAAATATATGCCGTACAACCACCAGCACAAATACTTCTTCCCTAATTGGGCCCCCAGC
CTTGCTGCCTCTCTACTTCCAGTGGTATATTTTCTATTTTGTATCCAGCGAAAGAAGTGGGTG
GACTTGGCCTGGATGATTACCTTCTACGTCGCTTCTTCCCTCACTTATGTGCCACTATTGGGGC
TGAAAGCCTTCTTGGGCTTTTCTTCATAGTCAGGTTCTTGGAAAGCAACTGGTTTGTGTGGGT
GACACAGATGAACCATATTCCCATGCACATTGATCATGACCGGAACATGGACTGGGTTTCCACC
CAGTCCAGGCCACATGCAATGTCCACAAGTCTGCCTTCAATGACTGGTTTCACTGGACACCTCA
ACTTCCAGATTGAGCACCATCTTTTCCACGATGCCTCGACACAATTACCACAAAGTGGCTCC
CCTGGTGCAGTCCTTGTGTGCCAAGCATGGCATAGAGTACCAGTCCAAGCCCCCTGCTGTCAGCC
TTCGCCGACATCATCCACTCACTAAAGGAGTCAGGGCAGCTCTGGCTAGATGCCTATCTTCACC
AATBACAACAGCCACCCTGCCAGTCTGGAAGAAGAGGAGGAAGACTCTGGAGCCAAGGCAGAG
GGGAGCTTGAGGGACAATGCCACTATAGTTTAATACTCAGAGGGGGTTGGGTTGGGGACATAA
AGCCTCTGACTCAAACCTCCTCCCTTTTATCTTCTAGCCACAGTTCTAAGACCCAAAGTGGGGGG
TGGACACAGAAGTCCCTAGGAGGGAAGGAGCTGTTGGGGCAGGGGTGTAAATTATTTCTTTT
CTAGTTTGGCAGATGCAGGTAGTTGGTGACAGAGAGAACCAGGAGGGTAACAGAAAGGAGGG
ACCTACTGAACCCAGAGTCAGGAAGAGATTTAACAATAAAATTCACCTCATGCCGGGCGTGGTG
CACGCGCCTGTAATCCAGCTACCCAGGAGGCTGAGGCAGGAGAATCGCTTGAACCGGGGAGGT
GGAGGTTGCAGTGAGCTGAGATCACGCCATTGTACTCCAGCCTGGGCGACAGAGCAAGACTCCA
TTTCAAAAAAAAAAAAAAAAAAAAAAAAAATCCACTCATATAAAAGGTGAGCTCAGCTCACTGGTCC
ATTTCTCAGTGGCTTCTCCATCCTCATTTGCAAACCTCAGAGGGATAAGGCAGTTGAACCTGAT
GAGCAAGAATTATAACAGCAAGGAAACATTAATGCTTAGAATTCTGAGATCCAGCACAACTCAG
TCGTGGGAGCTCAGCTCGCTGCCAGGGATAGGTATGACCTATGTCTGCCTTAGGCTGCTGGG
AGATGCCATTCTCCAGTTTCAGAAGCAGGCAGGGCAAAGGTCAAGACTGTGGTATTGGGGTCTT
TTGGCTCTGAAGGATCCTGGAACCACTGATTTTGGTTTATTCCCTCCAGGGTCTAAAGAGAACA
AGAGGTGCTAGCTCTTACCAAAACAGATGGTAGAGAGAGTTGCTGGCTATTTAAAAAGCTCTTT
CATCTTTTAATTACCTCTTCTTTTACCTCTTTAACCCTCCTCAGGAACAGAACACTTCTAG
GACTGGGGGTCTTTTAGCTCCATAAGCAAGTGAGCAGATGGGACAAGTTAGTCTTTTCTCCCTA
GAAACAAAGGGGATGCCAGTGGTTTCCCTTTGCTTCCCAACCTAAAATTTCAAGTTTAATAAA
ATAGCAATTAGCAGAAGTGACCAAATTGGGAGATAATTATCAGTCATGAGGAAAGACACAGATT
TCGGTCATAAAGAATGTAAGGGCTATAAGTAGAAAACCTTTCTATAACCTAAATGATGTTATAGAA
TTATTTTTGAGCAGGAGCAGAAAAGATTAAATATGATCACTTCATACTTCTAAATCAGAAATAGG
AAGATTAACACAGAACAGTTTGTGATTTCTATTGCTGGTAGCTAGGTATCTTACTCTGTCC
ACTCTTGTTCAGTATCTAACTCTTCTGAAACCAAATAGGCTTTAGAAGAGATTATCCTATAT
TCCTATCAGTATAATACTAAAATGTAACCTTTTAAATCATCTGGTTTTTAAAGATAAACAGTTT

Fig. 3 cont.

AGCCCATCTCTCCAGAGAGCAAACATAGGAATATGACTCAGGAGCCTCCTAGGGCTTATCATCA
GCCCTCACACCCGCTTCCCCCTCCAACCCACAGCCTTTGCTTCCAGGTGGCAGGATTACTACTT
TGCCTCTTCAGCAGCATCTACTCTAGGCATATTGATCATTTTAGACACTGGGAGAAGAGAACCT
CAAAGTAGGAGGAAAAGACAGAGCCTCCACTTAGTTTTGGGAGGGGATGGCAGACAGTCAAGGA
GATGAGCGTCCTAAGGCATGTTGGGATAGGGTCAGATGCACCACCCATGGAGAGGTTTGTCAAC
ACAAAGACATGGAAGGTTAGAGGTTTGTCAACAAAAAGACATGGAAGGTTAGGTTTGTCAACAC
AAAGACATGGAAGATTAGAGGTTTGTCAACACAAAGATACAGGAAGAATGGGCTGCAGAAGATT
TAGATGTTTTCCATTTGGGCACATTTTACTTAGCTGGAGAACTAGGTTTAAAACAGCCTGGGTA
GGAAAATTAGAAGCAAGCTGGATGCAGTGGCTCATGCCTGTAATCCCAACACTTTTGGGAGGTC
CAGGCAGGAGGATCACTTGGGCCCAGGAGGTCAAGCCTGCAGCGAGCTGAGATCACACCACTGC
ACTCCAGCCTGGGGTGATAGAACAGACCCTGTCTCAAAAAAAAAAAAAAAAAACAACAAAACTTA
GAATTGAGGAGTTGTACCTCCATTGGCTTCCTCACTCCAAAATAGGTGCTGATCCTTCCTATTC
CTATTCTTTGCCACCTTTTGGGTGTGGTGTCAACAGCCTGTTTAGCCAAGTAGCTTTGGGCATA
GGCTGCCCAATCTGAGCAAAACACCAGTGAGGCTCTATTGAGCAAGACCAAGTCCTCAAAGCACC
TGAACCACTGTGGCCTTCTCAGCCTACAGCAGTGTGGTCTCTTACATGGCCACAAAGGGACACA
CAGTGACAAAAGGCTCGGAATGTTACAATGGTAAAATGAGTGATCTCAAATCCACTGACAGATA
TAAAATAGGCTTAGAGAGGAAAAGCTGCCTCTGGTCAAGTAGATCATGGCAGCATGAATTCCAA
CTCACTTTTTTACGAACTCCAACCTTCTATGTTTATCTTTGTTACTTTCACTTTTTTACAACCTG
NCAGAGGCATTTTTTAAATCAGGCCCAATATCAGTATTCTTTTGTGTGTGCCAATTTTGTAT
CACATCCCTATGAAGTTGAAAAATAAAGTTAATTTTGACCAAAAG

Fig. 4**FADS2 cDNA**

CGTCACAGTCGGCAGGCAGCATGGGGAAGGGAGGGAACCAGGGCGAGGGGGCCGCCGAGCGCGA
GGTGTGGTGGCCACCTTCAGCTGGGAGGAGATTGAGAAGCATAACCTGCGCACCGACAGGTGG
CTGGTCATTGACCGCAAGGTTTACAACATCACCAAATGGTCCATCCAGCACCCGGGGGGCCAGC
GGGTGATCGGGCACTACGCTGGAGAAGATGCAACGGATGCCTTCCGCGCCTTCCACCCTGACCT
GGAATTCGTGGGCAAGTTCTTGAAACCCCTGCTGATTGGTGAAGTGGCCCCGGAGGAGCCAGC
CAGGACCACGGCAAGAACTCAAAGATCACTGAGGACTTCCGGGCCCTGAGGAAGACGGCTGAGG
ACATGAACCTGTTCAAGACCAACCACGTGTTCTTCCCTCCTCCTGGCCACATCATCGCCCT
GGAGAGCATTGCATGGTTCCTGTCTTTTACTTTGGCAATGGCTGGATTCTTACCCTCATCAG
GCCTTTGTCTTGTACCTCTCAGGCCCAAGCTGGATGGCTGCAACATGATTATGGCCACCTGT
CTGTCTACAGAAAACCAAGTGAACACCTTGTCCACAAATTCGTGATTGGCCACTTAAAGGG
TGCTCTGCCAACTGGTGAATCATCGCCACTTCCAGCACCACGCCAAGCCTAACATCTTCCAC
AAGGATCCCGATGTGAACATGCTGCACGTGTTTGTCTGGGCGAATGGCAGCCCATCGAGTACG
GCAAGAAGAAGCTGAAATACCTGCCCTACAATCACCAGCACGAATACTTCTTCCCTGATTGGGCC
GCCGCTGCTCATCCCCATGTATTTCCAGTACCAGATCATCATGACCATGATCGTCCATAAGAAC
TGGGTGGACCTGGCCTGGGCCGTGAGCTACTACATCCGGTCTTCATCACCTACATCCCTTTCT
ACGGCATCCTGGGAGCCCTCCTTTTCTCAACTTCATCAGGTTCTTGGAGAGCCACTGGTTTGT
GTGGGTACACAGATGAATCACATCGTCATGGAGATTGACCAGGAGGCCTACCGTGACTGGTTC
AGTAGCCAGCTGACAGCCACCTGCAACGTGGAGCAGTCTTCTTCAACGACTGGTTCAGTGGAC
ACCTTAACCTCCAGATTGAGCACCACTCTTCCCCACCATGCCCCGGCACAACTTACACAAGAT
CGCCCCGTGGTGAAGTCTCTATGTGCCAAGCATGGCATTGAATACCAGGAGAAGCCGCTACTG
AGGGCCCTGCTGGACATCATCAGGTCCCTGAAGAAGTCTGGGAAGCTGTGGCTGGACGCCTACC
TTCACAAATGAAGCCACAGCCCCCGGGACACCGTGGGGAAGGGGTGCAGGTGGGGTGATGGCCA
GAGGAATGATGGGCTTTTGTCTGAGGGGTGTCCGAGAGGCTGGTGTATGCACTGCTCACGGAC
CCCATGTTGGATCTTTCTCCCTTTCTCCTCTCCTTTTTCTCTTACATCTCCCCCATAGCACCC
TGCCCTCATGGGACCTGCCCTCCCTCAGCCGTGAGCCATCAGCCATGGCCCTCCCACTGCTCC
TAGCCCTTCTTCCAAGGAGCAGAGAGGTGGCCACCGGGGGTGGCTCTGTCTACCTCCACTCT
CTGCCCCCTAAAGATGGGAGGAGACCAGCGGTCCATGGGTCTGGCCTGTGAGTCTCCCCCTTGACG
CCTGGTCACTAGGCATCACCCCCGCTTTGGTTCTTCAGATGCTCTTGGGGTTCATAGGGGACAGG
TCCTAGTCGGGCAGGGCCCCCTGACCTCCCGGCCTGGCTTCACTCTCCCTGACGGCTGCCATTG
GTCCACCCTTTTCATAGAGAGGCCTGCTTTGTTACAAAGCTCGGGTCTCCCTCCTGCAGCTCGGT
TAAGTACCCGAGGCCTCTCTTAAGATGTCCAGGGCCCCAGGCCCCGCGGCACAGCCAGCCCAA
CCTTGGGCCCTGGAAGAGTCTTCCACCCCATCACTAGAGTGTCTGACCCTGGGCTTTCACGGG
CCCCATTCCACCGCCTCCCCAACTTGAGCCTGTGACCTTGGGACCAAGGGGGAGTCCCTCGTC
TCTTGTGACTCAGCAGAGGCAGTGGCCACGTTTCAAGGAGGGGCGGCTGGCCTGGAGGCTCAGC
CCACCCTCCAGCTTTTCTCAGGGTGTCTGAGGTCCAAGATTCTGGAGCAATCTGACCCTTCT
CCAAAGGCTCTGTTATCAGCTGGGCAGTGCCAGCCAATCCCTGGCCATTTGGCCCCAGGGGACG
TGGGCCCTGCAGGCTGCAGGAGGGCACTGGAGCTGGGAGGTCTCGTCCCAGCCCTCCCCATCTC
GGGGCTGTGTGTGGACGGCGCTGCCTCAGGCACTCTCCTGTCTGAACCTGCCCTTACTGTGTT
TAACCTGTTGCTCCAGGATGCATTCTGATAGGAGGGGGCGGCAGGGCTGGGCCCTTGTGACAATC
TGCCCTTTCACCACATGGCCTTGCCCTCGGTGGCCCTGACTGTGAGGAGGEGCAGGGAGGAGCAG
CGGGAGGGAGTCTCAGGAGGAGGCTGCCCTGAGGGGCTGGGAGGGGGTACCTCATGAGCACCA
GGGTGGAGCTGAGAAGAGGAGGAGGTGGGGGCTGGAGGTGCTGGTAGCTGAGGGGACGGGCAAG
TGAGAGGGGAGGGAGGGAAGTCTTGGGAGGATCCTGAGCTGCTGTTGAGTCTAACCCACTAAT
CAGTTCTTAGATTACGGGGAAGGGCAGGCACCAACAACCTCAGAATGGGGGCTTTTCGGGGAGGGC
GCCTAGTCCCCCAGCTCTAAGCAGCCAGGAGGGACCTGCATCTAAGCATCTGGGTTGCCATGG
CAATGGCATGCCCCCAGCTACTGTATGCCCCGACCCCGCAGAGGCAGAATGAACCCATAGG

Fig. 5

FADS3 cDNA

GGCCGCGGCGGCAGGGCGGGGCCGGAGCAGCGGGCGGCGGGGAGGCGGCGCCGGGAGCGCTC
TTCGCTTCCCTCGGGGTCTTGCTCGGACCTCGGCCACCGCCTGGGATCCCCAGGACTCGTGCGT
GCAGCATGGGCGGCGTCTGGGAGCCGGGACCGCGGGAGGGACCCGCGCAGCCGGGGGCACCGCT
GCCACCTTCTGCTGGGAGCAGATCCGCGCGCACGACCAGCCCGGCGACAAGTGGCTGGTCATC
GAGCGCCGCGTCTACGACATCAGCCGCTGGGCACAGCGGCACCCAGGGGGCAGCCGCCTCATCG
GCCACCACGGCGCTGAGGACGCCACGGATGCCTTCCGTGCCTTCCATCAAGATCTCAATTTTGT
GCGCAAGTTCTACAGCCCCTGTTGATTGGAGAGCTGGCTCCGGAAGAACCCAGCCAGGATGGA
CCCCTGAATGCGCAGCTGGTTCGAGGACTTCCGAGCCCTGCACCAGGCAGCCGAGGACATGAAGC
TGTTTGATGCCAGTCCACCTTCTTTGCTTTTCTACTGGGCCACATCCTGGCCATGGAGGTGCT
GGCCTGGCTCCTTATCTACCTCCTGGGTCTGGCTGGGTGCCAGTGCCCTGGCCGCCTTCATC
CTGGCCATCTCTCAGGCTCAGTCTGGTGTCTGCAGCATGACCTGGGCCATGCCTCCATCTTCA
AGAAGTCTGTGGTGAACACAGTGGCCCAAGTTCGTGATGGGGCAGCTAAAGGGCTTCTCCGC
CCACTGGTGGAACCTCCGCCACTTCCAGCACCACGCCAAGCCCAACATCTTCCACAAAGACCCA
GACGTGACGGTGGCGCCCGTCTTCTCCTGGGGGAGTCATCCGTGAGTATGGCAAGAAGAAAC
GCAGATACCTACCTACAACCAGCAGCACCTGTACTTCTTCTGATCGGCCCGCCGCTGCTCAC
CCTGGTGAACCTTGAAGTGGAAAATCTGGCGTACATGCTGGTGTGCATGCAGTGGGCGGATTTG
CTCTGGGCCCGCCAGCTTCTATGCCCGCTTCTTCTTATCCTACCTCCCCTTCTACGGCGTCCCTG
GGGTGCTGCTCTTCTTTGTTGCTGTCAGGGTCTTGAAAGCCACTGGTTCGTGTGGATCACACA
GATGAACCACATCCCCAAGGAGATCGGCCACGAGAAGCACCGGGACTGGGTGAGTCTCAGCTG
GCAGCCACCTGCAACGTGGAGCCCTCACTTTTACCAACTGGTTCAGCGGGCACCTCAACTTCC
AGATCGAGCACCACCTCTTCCCCAGGATGCCGAGACACAACCTACAGCCGGGTGGCCCCGCTGGT
CAAGTCGCTGTGTGCCAAGCACGGCCTCAGCTACGAAGTGAAGCCCTTCTCACCAGCGCTGGTG
GACATCGTCAGGTCCCTGAAGAAGTCTGGTGACATCTGGCTGGACGCCTACCTCCATCAGTGAA
GGCAACACCCAGGCGGGCAGAGAAGGGCTCAGGGCACCAGCAACCAAGCCAGCCCCGGCGGGAT
CGATACCCCCACCCCTCCACTGGCCAGCCTGGGGGTGCCCTGCCTGCCCTCCTGGTACTGTTGT
CTTCCCCCTCGGCCCCCTCACATGTGTATTACAGCAGCCCTATGGCCTTGGCTCTGGGCCTGATGG
GACAGGGGTAGAGGGAAGGTGAGCATAGCACATTTTCTAGAGCCACAATTGGGGGAAAGCTGT
TATTTTATATTAATAACATTTCAGATGT

Fig. 6

FADS1

```

Met Ala Pro Asp Pro Val Ala Ala Glu Thr Ala Ala Gln Gly Pro Thr
1           5           10           15

Pro Arg Tyr Phe Thr Trp Asp Glu Val Ala Gln Arg Ser Gly Cys Glu
          20           25           30

Glu Arg Trp Leu Val Ile Asp Arg Lys Val Tyr Asn Ile Ser Glu Phe
          35           40           45

Thr Arg Arg His Pro Gly Gly Ser Arg Val Ile Ser His Tyr Ala Gly
          50           55           60

Gln Asp Ala Thr Asp Pro Phe Val Ala Phe His Ile Asn Lys Gly Leu
65           70           75           80

Val Lys Lys Tyr Met Asn Ser Leu Leu Ile Gly Glu Leu Ser Pro Glu
          85           90           95

Gln Pro Ser Phe Glu Pro Thr Lys Asn Lys Glu Leu Thr Asp Glu Phe
          100          105          110

Arg Glu Leu Arg Ala Thr Val Glu Arg Met Gly Leu Met Lys Ala Asn
          115          120          125

His Val Phe Phe Leu Leu Tyr Leu Leu His Ile Leu Leu Leu Asp Gly
          130          135          140

Ala Ala Trp Leu Thr Leu Trp Val Phe Gly Thr Ser Phe Leu Pro Phe
145          150          155          160

Leu Leu Cys Ala Val Leu Leu Ser Ala Val Gln Ala Gln Ala Gly Trp
          165          170          175

Leu Gln His Asp Phe Gly His Leu Ser Val Phe Ser Thr Ser Lys Trp
          180          185          190

Asn His Leu Leu His His Phe Val Ile Gly His Leu Lys Gly Ala Pro
          195          200          205

Ala Ser Trp Trp Asn His Met His Phe Gln His His Ala Lys Pro Asn
          210          215          220

Cys Phe Arg Lys Asp Pro Asp Ile Asn Met His Pro Phe Phe Phe Ala
225          230          235          240

Leu Gly Lys Ile Leu Ser Val Glu Leu Gly Lys Gln Lys Lys Lys Tyr
          245          250          255

Met Pro Tyr Asn His Gln His Lys Tyr Phe Phe Leu Ile Gly Pro Pro
          260          265          270

Ala Leu Leu Pro Leu Tyr Phe Gln Trp Tyr Ile Phe Tyr Phe Val Ile
          275          280          285

```

Fig. 6 cont.

Gln Arg Lys Lys Trp Val Asp Leu Ala Trp Met Ile Thr Phe Tyr Val
 290 295 300
 Arg Phe Phe Leu Thr Tyr Val Pro Leu Leu Gly Leu Lys Ala Phe Leu
 305 310 315 320
 Gly Leu Phe Phe Ile Val Arg Phe Leu Glu Ser Asn Trp Phe Val Trp
 325 330 335
 Val Thr Gln Met Asn His Ile Pro Met His Ile Asp His Asp Arg Asn
 340 345 350
 Met Asp Trp Val Ser Thr Gln Leu Gln Ala Thr Cys Asn Val His Lys
 355 360 365
 Ser Ala Phe Asn Asp Trp Phe Ser Gly His Leu Asn Phe Gln Ile Glu
 370 375 380
 His His Leu Phe Pro Thr Met Pro Arg His Asn Tyr His Lys Val Ala
 385 390 395 400
 Pro Leu Val Gln Ser Leu Cys Ala Lys His Gly Ile Glu Tyr Gln Ser
 405 410 415
 Lys Pro Leu Leu Ser Ala Phe Ala Asp Ile Ile His Ser Leu Lys Glu
 420 425 430
 Ser Gly Gln Leu Trp Leu Asp Ala Tyr Leu His Gln
 435 440

Fig. 7

FADS2

Met Gly Lys Gly Gly Asn Gln Gly Glu Gly Ala Ala Glu Arg Glu Val
 1 5 10 15
 Ser Val Pro Thr Phe Ser Trp Glu Glu Ile Gln Lys His Asn Leu Arg
 20 25 30
 Thr Asp Arg Trp Leu Val Ile Asp Arg Lys Val Tyr Asn Ile Thr Lys
 35 40 45
 Trp Ser Ile Gln His Pro Gly Gly Gln Arg Val Ile Gly His Tyr Ala
 50 55 60
 Gly Glu Asp Ala Thr Asp Ala Phe Arg Ala Phe His Pro Asp Leu Glu
 65 70 75 80
 Phe Val Gly Lys Phe Leu Lys Pro Leu Leu Ile Gly Glu Leu Ala Pro
 85 90 95
 Glu Glu Pro Ser Gln Asp His Gly Lys Asn Ser Lys Ile Thr Glu Asp
 100 105 110
 Phe Arg Ala Leu Arg Lys Thr Ala Glu Asp Met Asn Leu Phe Lys Thr
 115 120 125
 Asn His Val Phe Phe Leu Leu Leu Leu Ala His Ile Ile Ala Leu Glu
 130 135 140
 Ser Ile Ala Trp Phe Thr Val Phe Tyr Phe Gly Asn Gly Trp Ile Pro
 145 150 155 160
 Thr Leu Ile Thr Ala Phe Val Leu Ala Thr Ser Gln Ala Gln Ala Gly
 165 170 175
 Trp Leu Gln His Asp Tyr Gly His Leu Ser Val Tyr Arg Lys Pro Lys
 180 185 190
 Trp Asn His Leu Val His Lys Phe Val Ile Gly His Leu Lys Gly Ala
 195 200 205
 Ser Ala Asn Trp Trp Asn His Arg His Phe Gln His His Ala Lys Pro
 210 215 220
 Asn Ile Phe His Lys Asp Pro Asp Val Asn Met Leu His Val Phe Val
 225 230 235 240
 Leu Gly Glu Trp Gln Pro Ile Glu Tyr Gly Lys Lys Lys Leu Lys Tyr
 245 250 255
 Leu Pro Tyr Asn His Gln His Glu Tyr Phe Phe Leu Ile Gly Pro Pro
 260 265 270
 Leu Leu Ile Pro Met Tyr Phe Gln Tyr Gln Ile Ile Met Thr Met Ile
 275 280 285

Fig. 8

FADS3

Met Gly Gly Val Gly Glu Pro Gly Pro Arg Glu Gly Pro Ala Gln Pro
 1 5 10 15
 Gly Ala Pro Leu Pro Thr Phe Cys Trp Glu Gln Ile Arg Ala His Asp
 20 25 30
 Gln Pro Gly Asp Lys Trp Leu Val Ile Glu Arg Arg Val Tyr Asp Ile
 35 40 45
 Ser Arg Trp Ala Gln Arg His Pro Gly Gly Ser Arg Leu Ile Gly His
 50 55 60
 His Gly Ala Glu Asp Ala Thr Asp Ala Phe Arg Ala Phe His Gln Asp
 65 70 75 80
 Leu Asn Phe Val Arg Lys Phe Leu Gln Pro Leu Leu Ile Gly Glu Leu
 85 90 95
 Ala Pro Glu Glu Pro Ser Gln Asp Gly Pro Leu Asn Ala Gln Leu Val
 100 105 110
 Glu Asp Phe Arg Ala Leu His Gln Ala Ala Glu Asp Met Lys Leu Phe
 115 120 125
 Asp Ala Ser Pro Thr Phe Phe Ala Phe Leu Leu Gly His Ile Leu Ala
 130 135 140
 Met Glu Val Leu Ala Trp Leu Leu Ile Tyr Leu Leu Gly Pro Gly Trp
 145 150 155 160
 Val Pro Ser Ala Leu Ala Ala Phe Ile Leu Ala Ile Ser Gln Ala Gln
 165 170 175
 Ser Trp Cys Leu Gln His Asp Leu Gly His Ala Ser Ile Phe Lys Lys
 180 185 190
 Ser Trp Trp Asn His Val Ala Gln Lys Phe Val Met Gly Gln Leu Lys
 195 200 205
 Gly Phe Ser Ala His Trp Trp Asn Phe Arg His Phe Gln His His Ala
 210 215 220
 Lys Pro Asn Ile Phe His Lys Asp Pro Asp Val Thr Val Ala Pro Val
 225 230 235 240
 Phe Leu Leu Gly Glu Ser Ser Val Glu Tyr Gly Lys Lys Lys Arg Arg
 245 250 255
 Tyr Leu Pro Tyr Asn Gln Gln His Leu Tyr Phe Phe Leu Ile Gly Pro
 260 265 270
 Pro Leu Leu Thr Leu Val Asn Phe Glu Val Glu Asn Leu Ala Tyr Met
 275 280 285

Fig. 8 cont.

| | | | | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Leu | Val | Cys | Met | Gln | Trp | Ala | Asp | Leu | Leu | Trp | Ala | Ala | Ser | Phe | Tyr | 290 | 295 | 300 | |
| Ala | Arg | Phe | Phe | Leu | Ser | Tyr | Leu | Pro | Phe | Tyr | Gly | Val | Pro | Gly | Val | 305 | 310 | 315 | 320 |
| Leu | Leu | Phe | Phe | Val | Ala | Val | Arg | Val | Leu | Glu | Ser | His | Trp | Phe | Val | 325 | 330 | 335 | |
| Trp | Ile | Thr | Gln | Met | Asn | His | Ile | Pro | Lys | Glu | Ile | Gly | His | Glu | Lys | 340 | 345 | 350 | |
| His | Arg | Asp | Trp | Val | Ser | Ser | Gln | Leu | Ala | Ala | Thr | Cys | Asn | Val | Glu | 355 | 360 | 365 | |
| Pro | Ser | Leu | Phe | Thr | Asn | Trp | Phe | Ser | Gly | His | Leu | Asn | Phe | Gln | Ile | 370 | 375 | 380 | |
| Glu | His | His | Leu | Phe | Pro | Arg | Met | Pro | Arg | His | Asn | Tyr | Ser | Arg | Val | 385 | 390 | 395 | 400 |
| Ala | Pro | Leu | Val | Lys | Ser | Leu | Cys | Ala | Lys | His | Gly | Leu | Ser | Tyr | Glu | 405 | 410 | 415 | |
| Val | Lys | Pro | Phe | Leu | Thr | Ala | Leu | Val | Asp | Ile | Val | Arg | Ser | Leu | Lys | 420 | 425 | 430 | |
| Lys | Ser | Gly | Asp | Ile | Trp | Leu | Asp | Ala | Tyr | Leu | His | Gln | | | | 435 | 440 | 445 | |

Fig. 9

Oligonucleotide primers to amplify FADS1 cDNA

TU12-R5 (5'-CGCCTGACAGCCCCTGCT-3')

TU12-F10 (5'-CAGGTGGCCAATCACAAAAT-3')

TU12-R7 (5'-CTCAAAGTGGAAACCATCTGCTA-3')

TU12-F9 (5'-GGAAACCCAGTCCATGTTCC-3')

TU12-R6 (5'-CCTGGGCCCTTTTCTTCATAGT-3')

TU12-F5 (5'-CTCAAGCTCCCTCTGCCT-3')

Oligonucleotide primers to amplify FADS2 cDNA

TU13-R4 (5'-TCAGAAGCATAACCTGCGC-3')

TU13-F7 (5'-CCAGTTCACCAATCAGCAGG-3')

TU13-R3 (5'-CCCCTGCTGATTGGTGAAC-3')

TU13-F4 (5'-TGTAGGGCAGGTATTTTCAGC-3')

TU13-R2 (5'-AGCCCATCGAGTACGGCAA-3')

TU13-F1 (5'-CCTCAGAACAAAAGCCCATC-3')

Oligonucleotide primers to amplify FADS3 cDNA

TU19-R2 (5'-TCTTGCTCGGACCTCGGC-3')

TU19-F2 (5'-GTGATCCACACGAACCAGTG-3')

TU19-R3 (5'-GAAGAACCCAGCCAGGATG-3')

TU19-F3 (5'-ACAGCTTCCCCCAATTCTC-3')

SEQUENCE LISTING

<110> MultiGene Biotech GmbH

5 <120> cDNA molecules of the members of gene family encoding
human fatty acid desaturases and their use in diagnosis
and therapy

10 <130> Anm. 99/002 WO

<140>
<141>

15 <150> EP 99104664.0
<151> 1999-03-09

<160> 22

20 <170> PatentIn Ver. 2.1

<210> 1
<211> 4205
<212> DNA
<213> Unknown Organism

25 <220>
<223> Description of Unknown Organism:

30 unknown

<400> 1

| | | | | | | |
|-------------|-------------|------------|------------|------------|------------|------|
| cactcctgga | gcccgcggac | cccgagcacg | cgctgacag | cccctgctgg | cccggcgcg | 60 |
| ggcgctcgcca | ggccagctat | ggcccccgac | ccggtggccg | ccgagaccgc | ggctcaggg | 120 |
| cctaccccg | gctacttcac | ctgggacgag | gtggcccgac | gctcagggg | cgaggagcg | 180 |
| tggtctagtga | tcgaccgtaa | ggtgtacaac | atcagcgagt | tcacccgccc | gcatccagg | 240 |
| ggctcccggg | tcacagcca | ctacgcccgg | caggatgcca | cggatccctt | tgtggccttc | 300 |
| cacatcaaca | agggccttgt | gaagaagtat | atgaactctc | tcctgattgg | agaactgtct | 360 |
| ccagagcagc | ccagctttga | gcccaccaag | aataaagagc | tgacagatga | gttccgggg | 420 |
| ctgcgggcca | cagtggagcg | gatggggctc | atgaaggcca | accatgtctt | cttcctgctg | 480 |
| tacctgtg | acatcttgct | gctggatggt | gcagcctggc | tcaccccttg | ggctcttggg | 540 |
| acgtcccttt | tgccttccct | cctctgtg | gtgctgctca | gtgcagttca | ggcccaggct | 600 |
| ggctggctgc | agcatgactt | tgggcacctg | tcggtcttca | gcacctcaaa | gtggaaccat | 660 |
| ctgctacatc | atcttgtgat | tggccacctg | aagggggccc | ccgccagttg | gtggaaccac | 720 |
| atgcacttcc | agcaccatgc | caagccaac | tgcttccgca | aagaccaga | catcaacatg | 780 |
| catcccttct | tctttgcctt | ggggaagatc | ctctctgtgg | agcttgggaa | acagaagaaa | 840 |
| aaatatatgc | cgtacaacca | ccagcacaaa | tacttcttcc | taattggggc | cccagccttg | 900 |
| ctgctctctc | acttccagtg | gtatatcttc | tattttgtta | tccagcgaaa | gaagtgggtg | 960 |
| gacttggcct | ggatgattac | cttctacgtc | cgcttcttcc | tcacttatgt | gccactattg | 1020 |
| gggcrgaaag | ccttccctggg | ccttttcttc | atagtcaggt | tcctggaaag | caactgggtt | 1080 |
| gtgtgggtga | cacagatgaa | ccatattccc | atgcacattg | atcatgaccg | gaacatggac | 1140 |
| tgggcttcca | cccagctcca | ggccacatgc | aatgtccaca | agtctgcctt | caatgactgg | 1200 |
| ttcagtgagc | acctcaactt | ccagattgag | caccatcttt | ttcccacgat | gcctcgacac | 1260 |
| aattaccaca | aagtggctcc | cctgggtgag | tccttgtgtg | ccaagcatgg | catagagtac | 1320 |
| cagtccaagc | ccctgctgtc | agccttcgcc | gacatcatcc | actcactaaa | ggagtcaggg | 1380 |
| cagctctggc | tagatgccta | tcttcacca | taacaacagc | caccctgccc | agtctggaag | 1440 |
| aagaggagga | agactctgga | gccaaggcag | aggggagctt | gagggacaat | gccactatag | 1500 |
| tttaatactc | agaggggggt | gggtttgggg | acataaagcc | tctgactcaa | actcctccct | 1560 |
| tttatcttct | agccacagtt | ctaagaccga | aagtgggggg | tggacacaga | agtccttagg | 1620 |
| aggggaaggag | ctgttggggc | aggggtgtaa | attatttcct | ttttctagtt | tggcacatgc | 1680 |
| aggtagtgtg | tgaacagaga | gaaccaggag | ggtaacagaa | gaggaggagc | ctactgaacc | 1740 |
| cagagtcaag | aagagattta | acactaaaat | tccactcatg | ccgggctgtg | tgacgcgcc | 1800 |
| tgtaatccca | gctacccagg | aggctgaggc | aggagaatcg | cttgaaccgg | ggaggtggag | 1860 |


```

gttgacagtga gctgagatca cgcatttcta ctccagcctg ggcgacagag caagactcca 1920
tttcaaaaaa aaaaaaaaaa aaaaaaatcc actcatataa aaggtgagct cagctcactg 1980
gtccatttct cagtggcttc tccatcctca tttccaaacc tcagagggat aaggcagttg 2040
aacctgatga gcaagaatta taacagcaag gaaacattaa tgcttagaat tctgagatcc 2100
5 agcacaaactc agtctgtggg agctcagctc gctgcccagg gatagggtatg acctatgtct 2160
gccttaggct gctgggagat gccattctcc agtttcagaa gcaggcaggg caaagggtcaa 2220
gactgtggta tgggggtctt ttgggtctga aggatcctgg aaccactgat tttggtttat 2280
tccctccagg gctaaagag aacaagaggt gctagctctt accaaaaacag atggtagaga 2340
gagttgctgg ctatttaaaa agctctttca tcttttaatt cacctcttct tttcacctct 2400
10 ttaaccactc ctcaggaaca gaacacttct aggactgggg gtcttttagc tccataagca 2460
agtgagcaga tgggacaagt tagtcttttc tccctagaaa caaaggggat gccagtggt 2520
ttccctttgc ttcccaacct aaaatttcaa gttaataaaa atagcaatta gcagaagtga 2580
ccaaattggg agataattat cagtcagtag gaaagacaca gatttcggtc ataaagaatg 2640
taagggttat aagtagaaac tttctataac ctaaagtatg ttatagaatt atttttgagc 2700
15 aggagcagaa agattaaata tgatcacttc atacttctaa atcagaaata ggaagattaa 2760
aaccacagaa cagtttgtga tttctattgc tggtagctag gtatcttact ctgtccactc 2820
ttgttcaagt atctaactct tctggaaacc aaataggctt tagaagagat tatcctatat 2880
tccctatcagt ataatactaa aatgtaactt tttaatcatc tggtttttaa aagataaaca 2940
gttttagcca tctctccaga gagcaaacat aggaatatga ctcaggagcc tccatagggt 3000
20 tatcatcagc cctcacaccc gcttccccct ccaacccaca gcctttgctt ccagggtggca 3060
ggattactac tttgctctt cagcagcatc tactctaggc atattgatca ttttagacac 3120
tgggagaaga gaacctcaaa ctaggaggaa aagacagagc ctccacttag ttttgggagg 3180
ggatggcaga cagtcaagga gatgagcgtc ctaaggcatg ttgggatagg gtcagatgca 3240
ccacccatgg agaggtttgt caacacaaag acatggaagg tttagaggtt gtcaacaaaa 3300
25 agacatggaa ggttaggttt gtcaacacaa agacatggaa ctagtagagg ttgtcaacac 3360
aaagatacag gaagaatggg ctgcagaaga tttagatgtt ttccatttgg gcacatttta 3420
cttagctgga gaactagggt taaaacagcc tgggtaggaa aattagaagc aagctggatg 3480
cagtggctca tgctgtaat cccaacactt ttgggaggtc caggcaggag gatcacttgg 3540
30 gccaggagg tcaagcctgc agcgagctga gatcacacca ctgcactcca gcctggggtg 3600
atagaacaaag accctgtctc aaaaaaataa aaaaacaaca aaaacttaga attgaggagt 3660
tgtacctcca ttggcttctt cactccaaaa taggtgtgta tcttccctat tccattctt 3720
tgccaccttt tgggtgtggg gtcaccagcc tgtttagcca agtagctttg gccataggct 3780
gccaatctg agcaaacacc agtgaggctc tattgagcaa gaccaagtcc tcaaagcacc 3840
35 tgaaccactg tggccttctc agcctacagc agtgtggtct ctacatggc cacaagggga 3900
cacacagtga caaaaaggctc ggaatgttac aatggtaaaa tgagtgatc caaatccact 3960
gacagatata aaataggctt agagaggaaa agctgcctct ggtcaagtag atcatggcag 4020
catgaattcc aactcacttt ttacgaact ccaacttcta tgtttatctt tgttactttc 4080
acttttttac aacctgncag aggcattttt taaatcaggc ccaatatcag tatcttttt 4140
40 gtgtgtgcca attttgttat cacatcccta tgaagtga aaataaagtt aattttgacc 4200
aaaag 4205

```

<210> 2

<211> 4089

<212> DNA

45 <213> Unknown Organism

<220>

<223> Description of Unknown Organism:

50 unknown

<400> 2

```

cgtcacagtc ggcaggcagc atggggaggg gaggaacca gggcgagggg gccgcagagc 60
55 gcgaggtgtc ggtgccacc ttcagctggg aggagattca gaagcataac ctgcgcaccg 120
acagggtggct ggtcattgac cgcaaggttt acaacatcac caaatggtcc atccagcacc 180
gcggggggcca gcgggtcatc gggcactacg ctggagaaga tgcaacggat gccttcgagc 240
ccttccaccc tgacctggaa ttcgtgggca agttcttgaa accctcgctg attggtgaac 300
tgcccccgga ggagcccagc caggaccacg gcaagaactc aaagatcact gaggacttcc 360
60 ggqccctgaq qaaqacgqct gaggacatga acctgttcaa gaccaaccac gtgttcttcc 420
tcttctctct ggcccacatc atcgccctgg agagcattgc atggttctac gtcttttact 480
ttggcaatgg ctggattctt accctcatca cggcctttgt ccttgctacc tctcaggccc 540
aagctggatg cctgcaacat gattatggcc acctgtctgt ctacagaaaa cccaagggga 600

```

| | | | | | | | |
|----|-------------|------------|-------------|-------------|-------------|-------------|------|
| | accaccttgt | ccacaaatc | gtcattggcc | acttaaagg | tgcctctgcc | aactgggtgga | 660 |
| | atcatcgcca | cttcagcac | cacgccaagc | ctaacatctt | ccacaaggat | cccgatgtga | 720 |
| | acatgtgca | cgtgtttgtt | ctgggcgaat | ggcagcccat | cgagtacggc | aagaagaagc | 780 |
| 5 | tgaataacct | gccctacaat | caccagcacg | aatacttctt | cctgattggg | ccgccgctgc | 840 |
| | tcatccccat | gtatttccag | taccagatca | tcatgacct | gatcgccat | aagaactggg | 900 |
| | tggacctggc | ctgggccgtc | agctactaca | tccggttctt | catcacctac | atcccttctt | 960 |
| | acggcatcct | gggagccctc | cttttccctc | acttcatcag | gttcctggag | agccactggt | 1020 |
| | ttgtgtgggt | cacacagatg | aatcacatcg | tcatggagat | tgaccaggag | gcctaccctg | 1080 |
| 10 | actggttcag | tagccagctg | acagccacct | gcaacgtgga | gcagtccctc | ttcaacgact | 1140 |
| | ggttcagtgg | acaccttaac | ttccagattg | agcaccacct | cttccccacc | atgccccggc | 1200 |
| | acaacttaca | caagatcgcc | ccgctgggtga | agtctctatg | tgccaagcat | ggcattggaat | 1260 |
| | accaggagaa | gccgctactg | agggccctgc | tggacatcat | cagggtccctc | aagaagtctg | 1320 |
| | ggaagtctgt | gctggacgcc | taccttcaca | aatgaagcca | cagcccccg | gacaccgtgg | 1380 |
| 15 | ggaaggggtg | caggtggggt | gatggccaga | ggaatgatgg | gcttttgttc | tgaggggtgt | 1440 |
| | ccgagaggct | ggtgtatgca | ctgctcacgg | accccatggt | ggatctttct | ccctttctcc | 1500 |
| | tctctctttt | ctcttcacat | ctccccata | gcacctggc | ctcatgggac | ctgcccctcc | 1560 |
| | tcagccgtca | gccatcagcc | atggccctcc | cagtgcctcc | tagccccttc | ttccaaggag | 1620 |
| | cagagagggtg | gccaccgggg | gtggctctgt | cctacctcca | ctctctgccc | ctaaagatgg | 1680 |
| 20 | gaggagacca | gcggtccatg | ggtctggcct | gtgagtctcc | ccttgccagcc | tggtcactag | 1740 |
| | gcatcacccc | cgctttggtt | cttcagatgc | tcttgggggt | cataggggca | ggtcctagtc | 1800 |
| | gggcaggggc | cctgaccctc | ccggcctggc | ttcactctcc | ctgacggctg | ccattgggtc | 1860 |
| | acccttctcat | agagaggcct | gctttgttac | aaagctcggg | tctccctcct | gcagctcggg | 1920 |
| | taagtaccog | aggcctctct | taagatgtcc | agggcccccag | gcccgcgggc | acagccagcc | 1980 |
| 25 | caaaccttgg | gccttggaag | agtcctccac | cccataccta | gagtgtctctg | accctgggct | 2040 |
| | ttcacggggc | ccattccacc | gcctcccca | cttgagcctg | tgaccttgcg | accaaagggg | 2100 |
| | gagtcctctg | tctcttgtga | ctcagcagag | gcagtggcca | cgttcaggga | ggggccggct | 2160 |
| | ggcctggagg | ctcagcccac | cctccaqctt | ttcctcaggg | tgctctgagg | tccaagattc | 2220 |
| | tgagagaatc | tgaccttctt | ccaaaaggctc | tgttatcagc | tgggcagtg | cagccaatcc | 2280 |
| 30 | ctggccattt | ggccccaggg | gacgtgggcc | ctgcaggctg | caggagggca | ctggagctgq | 2340 |
| | gaggtctcgt | cccagccctc | cccactctgg | ggctgctgtg | tggaaggcgc | tgccctcaggc | 2400 |
| | actctcctgt | ctgaacctgr | cttactgtg | tttaacctgt | tgctccagga | tgcatctga | 2460 |
| | taggaggggg | cggcagggtg | gggccttgtg | acaatctgcc | tttcaccaca | tgcccttgcc | 2520 |
| | tcggtggccc | tgactgtcag | ggaggggcag | ggaggcagag | cgggaggggag | tctcaggagg | 2580 |
| 35 | aggctgcctt | gaggggctgg | ggagggggta | cctcatgagg | accagggtgg | agctgagaag | 2640 |
| | aggaggagggt | gggggctgga | ggtgtctggt | gctgagggga | cgggcgaagt | agaggggagg | 2700 |
| | gaggggaagtc | ctgggaggat | cctgagctgc | tgttgagtc | taaccacta | atcagttctt | 2760 |
| | agattcaggg | gaagggcagg | caccaacaac | tcagaatggg | ggcttctggg | gagggcgccct | 2820 |
| | agtcccccca | gctctaagca | gccaggaggg | acctgcattc | aagcatctgg | gttgccatgg | 2880 |
| 40 | caatggcatg | ccccccagct | actgtatgcc | cccgaccccc | gcagaggcag | aatgaacca | 2940 |
| | tagggagctg | atcgtaatgt | ttatcatgtt | acttccccac | ccctacattt | tttgaaataa | 3000 |
| | aataagggaat | tttattctca | cttctctgtt | ttcctgcacg | ccaatgccag | gccatggtat | 3060 |
| | tgggtgatag | atgaggccct | tctagctggg | cctgggcacc | aggagggggtc | ccatgctty | 3120 |
| | catctctctg | tatccccctc | ctccccgtg | gcatccccc | ccgcctctcc | ctgctgcctc | 3180 |
| 45 | tgaattcat | tctggggccc | ggaacttgg | ggaaatgacc | caaaaaacatt | ggcccatctt | 3240 |
| | cctcctctca | gcagccgacc | ccagcccaat | tctaaaacag | ggctgagagc | cacctctcag | 3300 |
| | cagctgaccc | ctacccaagg | aggggtggat | ggaggggctt | gcagagactc | ttcctaaccat | 3360 |
| | cctccccccc | cagctgtctc | cccaagtga | atctgcctc | ccatccctgg | gccagccagc | 3420 |
| | ttccacagag | gcgcaggcca | aacagaattc | ctggccctct | tggaaggggc | tggaagaaggc | 3480 |
| 50 | cgggagcagt | ggctcacgcc | tgtaatccca | gcactttggg | aggctgaggc | gggcagatca | 3540 |
| | caaagtcaag | agattgagac | catcctggcc | aacatggtga | aaccccgctc | ctactaaaaa | 3600 |
| | tacaaaaatt | aggccgggtg | cggtggctca | cgctgtaat | cccagcactt | tgggaggccg | 3660 |
| | aggcgggcag | atcacgaggt | caggagatca | agaccatcct | ggctaaccag | gtgaaacccc | 3720 |
| | gtcttacta | aaaatacaaa | aaattagctg | ggcgagggtg | cggtgacctg | tagccccagc | 3780 |
| 55 | tacgtgggag | gctgaggcaa | gagaatggng | tgaaccccg | cggggcagag | cctgcagaga | 3840 |
| | gctgagatca | caccaactgt | ctccagcctg | ggcgacagcg | agacucctc | tcaaaaaaaa | 3900 |
| | aaaaaaaaaa | aattagctgg | gcatggtgg | gcgtgcctgc | agtcacagct | actcaggagg | 3960 |
| | ctgagacggg | agaatcgctt | gaacctggga | ggcagagggt | gcagtgagcc | aagatcgctc | 4020 |
| | actccagcct | agcgacagag | tgagactcca | tctcaataa | ataaataaat | taattaatta | 4080 |
| 60 | aattaaatt | | | | | | 4089 |

<210> 3
 <211> 1757
 <212> DNA
 <213> Unknown Organism

5

<220>
 <223> Description of Unknown Organism:

10 unknown

<400> 3

| | | | | | | |
|------------|-------------|------------|-------------|------------|------------|------|
| ggccgcgccg | gcagggcgccg | gccggagcag | cggcgccgccg | cggagggccg | gcccgggagc | 60 |
| gctcttcgct | tccctcgccg | tcttgctcgg | acctcgccca | ccgcctggga | tccccaggac | 120 |
| tcgtgctgct | agcatggccg | gcgtcgccga | gccgggaccg | cgggagggac | ccgcgcagcc | 180 |
| ggggggcacc | ctgcccacct | tctgctggga | gcagatccgc | gcgcacgacc | agcccgccga | 240 |
| caagtggctg | gtcatcgagc | gccgcgtcta | cgacatcagc | cgtcgccgac | agccgcaccc | 300 |
| agggggcagc | cgccctcatc | gccaccacgg | cgtcgaggac | gccacggatg | ccttcctgtc | 360 |
| cttccatcaa | gatctcaatt | ttgtcgcaaa | gttcctacag | cccctgttga | ttggagagct | 420 |
| ggctccggaa | gaaccacagc | aggatggacc | cctgaatgcg | cagctggctg | aggacttccg | 480 |
| agccctgcac | caggcagccg | aggacatgaa | gctgtttgat | gccagtccca | ccttctttgc | 540 |
| tttctactgt | ggccacatcc | tgcccatgga | ggtgctggcc | tggtctccta | tctacctcct | 600 |
| gggtcctggc | tggttgccca | gtgccctggc | cgcccttcac | ctggccatct | ctcaggctca | 660 |
| gtcctggtgt | ctgcagcatg | acctgggcca | tgccctccatc | ttcaagaagt | cctgggtgga | 720 |
| ccagctggcc | cagaagtctg | tgatggggca | gctaaaggcc | ttctccgccc | actggtgqaa | 780 |
| cttcgcccac | ttccagcacc | acgccaagcc | caacatcttc | cacaaagacc | cagacgtgac | 840 |
| ggtggcgccc | gtcttctctc | tgggggagtc | atcgtctgag | tatggcaaga | agaaacgcag | 900 |
| atacctaccc | tacaaccagc | agcacctgta | cttcttctcg | atcggccccc | cgctgctcac | 960 |
| cctggtgaac | tttgaagtgg | aaaatctggc | gtacatgctg | gtgtgcatgc | agtgggcgga | 1020 |
| tttgctctgg | gccgccagct | tctatgcccc | cttcttctta | tcttacctcc | ccttctacgg | 1080 |
| cgctccctgg | gtgctgctct | tctttgttgc | tgtcagggtc | ctggaaagcc | actggttcgt | 1140 |
| gtgcatcaca | cagatgaacc | acatccccaa | ggagatcgcc | cacgagaagc | accgggactg | 1200 |
| ggtcagctct | cagctggcag | ccacctgcaa | cgtggagccc | tcacttttca | ccaactgggt | 1260 |
| cagcgggcac | ctcaacttcc | agatcgagca | ccacctcttc | cccaggatgc | cgagacacaa | 1320 |
| ctacagccgg | gtggccccgc | tggtcaagtc | gctgtgtgcc | aagcacggcc | tcagctacga | 1380 |
| agtcaagccc | ttcctcaccg | cgtcggtgga | catcgtcagg | tccctgaaga | agtctggtga | 1440 |
| catctggctg | gacgcctacc | tccatcagtg | aaggcaacac | ccaggcgggc | agagaagggc | 1500 |
| tcagggcacc | agcaaccaag | ccagccccgg | cgggatcgat | acccccaccc | ctccactggc | 1560 |
| cagcctgggg | gtgccctgac | tgccctctcg | gtactgttgt | cttccccctg | gccccctcac | 1620 |
| atgtgtattc | agcagcccta | tgcccttggc | tctgggcctg | atgggacagg | ggtagaggga | 1680 |
| aggtagcat | agcacattt | cctagagcga | gaattggggg | aaagctgtta | tttttatatt | 1740 |
| aaaatacatt | cagatgt | | | | | 1757 |

45

<210> 4
 <211> 444
 <212> PRT
 <213> Unknown Organism

50

<220>
 <223> Description of Unknown Organism:

unknown

<400> 4

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Ala | Pro | Asp | Pro | Val | Ala | Ala | Glu | Thr | Ala | Ala | Gln | Gly | Pro | Thr |
| 1 | | | | 5 | | | | 10 | | | | | 15 | | |
| Pro | Arg | Tyr | Phe | Thr | Trp | Asp | Glu | Val | Ala | Gln | Arg | Ser | Gly | Cys | Glu |
| | | | 20 | | | | 25 | | | | | | 30 | | |
| Glu | Arg | Trp | Leu | Val | Ile | Asp | Arg | Lys | Val | Tyr | Asn | Ile | Ser | Glu | Phe |
| | | 35 | | | | | 40 | | | | | 45 | | | |

60

Thr Arg Arg His Pro Gly Gly Ser Arg Val Ile Ser His Tyr Ala Gly
 50 55 60

5 Gln Asp Ala Thr Asp Pro Phe Val Ala Phe His Ile Asn Lys Gly Leu
 65 70 75 80

Val Lys Lys Tyr Met Asn Ser Leu Leu Ile Gly Glu Leu Ser Pro Glu
 85 90 95

10 Gln Pro Ser Phe Glu Pro Thr Lys Asn Lys Glu Leu Thr Asp Glu Phe
 100 105 110

15 Arg Glu Leu Arg Ala Thr Val Glu Arg Met Gly Leu Met Lys Ala Asn
 115 120 125

His Val Phe Phe Leu Leu Tyr Leu Leu His Ile Leu Leu Leu Asp Gly
 130 135 140

20 Ala Ala Trp Leu Thr Leu Trp Val Phe Gly Thr Ser Phe Leu Pro Phe
 145 150 155 160

Leu Leu Cys Ala Val Leu Leu Ser Ala Val Gln Ala Gln Ala Gly Trp
 165 170 175

25 Leu Gln His Asp Phe Gly His Leu Ser Val Phe Ser Thr Ser Lys Trp
 180 185 190

30 Asn His Leu Leu His His Phe Val Ile Gly His Leu Lys Gly Ala Pro
 195 200 205

Ala Ser Trp Trp Asn His Met His Phe Gln His His Ala Lys Pro Asn
 210 215 220

35 Cys Phe Arg Lys Asp Pro Asp Ile Asn Met His Pro Phe Phe Phe Ala
 225 230 235 240

Leu Gly Lys Ile Leu Ser Val Glu Leu Gly Lys Gln Lys Lys Lys Tyr
 245 250 255

40 Met Pro Tyr Asn His Gln His Lys Tyr Phe Phe Leu Ile Gly Pro Pro
 260 265 270

45 Ala Leu Leu Pro Leu Tyr Phe Gln Trp Tyr Ile Phe Tyr Phe Val Ile
 275 280 285

Gln Arg Lys Lys Trp Val Asp Leu Ala Trp Met Ile Thr Phe Tyr Val
 290 295 300

50 Arg Phe Phe Leu Thr Tyr Val Pro Leu Leu Gly Leu Lys Ala Phe Leu
 305 310 315 320

Gly Leu Phe Phe Ile Val Arg Phe Leu Glu Ser Asn Trp Phe Val Trp
 325 330 335

55 Val Thr Gln Met Asn His Ile Pro Met His Ile Asp His Asp Arg Asn
 340 345 350

60 Met Asp Trp Val Ser Thr Gln Leu Gln Ala Thr Cys Asn Val His Lys
 355 360 365

Ser Ala Phe Asn Asp Trp Phe Ser Gly His Leu Asn Phe Gln Ile Glu
 370 375 380

5 His His Leu Phe Pro Thr Met Pro Arg His Asn Tyr His Lys Val Ala
 385 390 395 400

Pro Leu Val Gln Ser Leu Cys Ala Lys His Gly Ile Glu Tyr Gln Ser
 405 410 415

10 Lys Pro Leu Leu Ser Ala Phe Ala Asp Ile Ile His Ser Leu Lys Glu
 420 425 430

Ser Gly Gln Leu Trp Leu Asp Ala Tyr Leu His Gln
 435 440

15

<210> 5
 <211> 444
 <212> PRT
 20 <213> Unknown Organism

<220>
 <223> Description of Unknown Organism:

25 unknown

<400> 5
 Met Gly Lys Gly Gly Asn Gln Gly Glu Gly Ala Ala Glu Arg Glu Val
 1 5 10 15

30 Ser Val Pro Thr Phe Ser Trp Glu Glu Ile Gln Lys His Asn Leu Arg
 20 25 30

35 Thr Asp Arg Trp Leu Val Ile Asp Arg Lys Val Tyr Asn Ile Thr Lys
 35 40 45

Trp Ser Ile Gln His Pro Gly Gly Gln Arg Val Ile Gly His Tyr Ala
 50 55 60

40 Gly Glu Asp Ala Thr Asp Ala Phe Arg Ala Phe His Pro Asp Leu Glu
 65 70 75 80

Phe Val Gly Lys Phe Leu Lys Pro Leu Leu Ile Gly Glu Leu Ala Pro
 85 90 95

45 Glu Glu Pro Ser Gln Asp His Gly Lys Asn Ser Lys Ile Thr Glu Asp
 100 105 110

50 Phe Arg Ala Leu Arg Lys Thr Ala Glu Asp Met Asn Leu Phe Lys Thr
 115 120 125

Asn His Val Phe Phe Leu Leu Leu Ala His Ile Ile Ala Leu Glu
 130 135 140

55 Ser Ile Ala Trp Phe Thr Val Phe Tyr Phe Gly Asn Gly Trp Ile Pro
 145 150 155 160

Thr Leu Ile Thr Ala Phe Val Leu Ala Thr Ser Gln Ala Gln Ala Gly
 165 170 175

60 Trp Leu Gln His Asp Tyr Gly His Leu Ser Val Tyr Arg Lys Pro Lys
 180 185 190

Trp Asn His Leu Val His Lys Phe Val Ile Gly His Leu Lys Gly Ala
 195 200 205
 5 Ser Ala Asn Trp Trp Asn His Arg His Phe Gln His His Ala Lys Pro
 210 215 220
 Asn Ile Phe His Lys Asp Pro Asp Val Asn Met Leu His Val Phe Val
 225 230 235 240
 10 Leu Gly Glu Trp Gln Pro Ile Glu Tyr Gly Lys Lys Lys Leu Lys Tyr
 245 250 255
 Leu Pro Tyr Asn His Gln His Glu Tyr Phe Phe Leu Ile Gly Pro Pro
 260 265 270
 15 Leu Leu Ile Pro Met Tyr Phe Gln Tyr Gln Ile Ile Met Thr Met Ile
 275 280 285
 20 Val His Lys Asn Trp Val Asp Leu Ala Trp Ala Val Ser Tyr Tyr Ile
 290 295 300
 Arg Phe Phe Ile Thr Tyr Ile Pro Phe Tyr Gly Ile Leu Gly Ala Leu
 305 310 315 320
 25 Leu Phe Leu Asn Phe Ile Arg Phe Leu Glu Ser His Trp Phe Val Trp
 325 330 335
 Val Thr Gln Met Asn His Ile Val Met Glu Ile Asp Gln Glu Ala Tyr
 340 345 350
 30 Arg Asp Trp Phe Ser Ser Gln Leu Thr Ala Thr Cys Asn Val Glu Gln
 355 360 365
 35 Ser Phe Phe Asn Asp Trp Phe Ser Gly His Leu Asn Phe Gln Ile Glu
 370 375 380
 His His Leu Phe Pro Thr Met Pro Arg His Asn Leu His Lys Ile Ala
 385 390 395 400
 40 Pro Leu Val Lys Ser Leu Cys Ala Lys His Gly Ile Glu Tyr Gln Glu
 405 410 415
 Lys Pro Leu Leu Arg Ala Leu Leu Asp Ile Ile Arg Ser Leu Lys Lys
 420 425 430
 45 Ser Gly Lys Leu Trp Leu Asp Ala Tyr Leu His Lys
 435 440
 50 <210> 6
 <211> 445
 <212> PRT
 <213> Unknown Organism
 55 <220>
 <223> Description of Unknown Organism:
 unknown
 60 <400> 6
 Met Gly Gly Val Gly Glu Pro Gly Pro Arg Glu Gly Pro Ala Gln Pro
 1 5 10 15

Gly Ala Pro Leu Pro Thr Phe Cys Trp Glu Gln Ile Arg Ala His Asp
 20 25 30
 5 Gln Pro Gly Asp Lys Trp Leu Val Ile Glu Arg Arg Val Tyr Asp Ile
 35 40 45
 Ser Arg Trp Ala Gln Arg His Pro Gly Gly Ser Arg Leu Ile Gly His
 50 55 60
 10 His Gly Ala Glu Asp Ala Thr Asp Ala Phe Arg Ala Phe His Gln Asp
 65 70 75 80
 Leu Asn Phe Val Arg Lys Phe Leu Gln Pro Leu Leu Ile Gly Glu Leu
 85 90 95
 15 Ala Pro Glu Glu Pro Ser Gln Asp Gly Pro Leu Asn Ala Gln Leu Val
 100 105 110
 20 Glu Asp Phe Arg Ala Leu His Gln Ala Ala Glu Asp Met Lys Leu Phe
 115 120 125
 Asp Ala Ser Pro Thr Phe Phe Ala Phe Leu Leu Gly His Ile Leu Ala
 130 135 140
 25 Met Glu Val Leu Ala Trp Leu Leu Ile Tyr Leu Leu Gly Pro Gly Trp
 145 150 155 160
 Val Pro Ser Ala Leu Ala Ala Phe Ile Leu Ala Ile Ser Gln Ala Gln
 165 170 175
 30 Ser Trp Cys Leu Gln His Asp Leu Gly His Ala Ser Ile Phe Lys Lys
 180 185 190
 35 Ser Trp Trp Asn His Val Ala Gln Lys Phe Val Met Gly Gln Leu Lys
 195 200 205
 Gly Phe Ser Ala His Trp Trp Asn Phe Arg His Phe Gln His His Ala
 210 215 220
 40 Lys Pro Asn Ile Phe His Lys Asp Pro Asp Val Thr Val Ala Pro Val
 225 230 235 240
 Phe Leu Leu Gly Glu Ser Ser Val Glu Tyr Gly Lys Lys Lys Arg Arg
 245 250 255
 45 Tyr Leu Pro Tyr Asn Gln Gln His Leu Tyr Phe Phe Leu Ile Gly Pro
 260 265 270
 50 Pro Leu Leu Thr Leu Val Asn Phe Glu Val Glu Asn Leu Ala Tyr Met
 275 280 285
 Leu Val Cys Met Gln Trp Ala Asp Leu Leu Trp Ala Ala Ser Phe Tyr
 290 295 300
 55 Ala Arg Phe Phe Leu Ser Tyr Leu Pro Phe Tyr Gly Val Pro Gly Val
 305 310 315 320
 Leu Leu Phe Phe Val Ala Val Arg Val Leu Glu Ser His Trp Phe Val
 325 330 335
 60 Trp Ile Thr Gln Met Asn His Ile Pro Lys Glu Ile Gly His Glu Lys
 340 345 350

His Arg Asp Trp Val Ser Ser Gln Leu Ala Ala Thr Cys Asn Val Glu
 355 360 365
 5 Pro Ser Leu Phe Thr Asn Trp Phe Ser Gly His Leu Asn Phe Gln Ile
 370 375 380
 Glu His His Leu Phe Pro Arg Met Pro Arg His Asn Tyr Ser Arg Val
 10 385 390 395 400
 Ala Pro Leu Val Lys Ser Leu Cys Ala Lys His Gly Leu Ser Tyr Glu
 405 410 415
 15 Val Lys Pro Phe Leu Thr Ala Leu Val Asp Ile Val Arg Ser Leu Lys
 420 425 430
 Lys Ser Gly Asp Ile Trp Leu Asp Ala Tyr Leu His Gln
 435 440 445
 20
 <210> 7
 <211> 18
 <212> DNA
 <213> Artifical Sequence
 25
 <220>
 <223> Description of Artifical Sequence:
 Primer
 30
 <400> 7
 cgccctgacag cccctgct 18
 35
 <210> 8
 <211> 20
 <212> DNA
 <213> Artifical Sequence
 40
 <220>
 <223> Description of Artifical Sequence:
 Primer
 45
 <400> 8
 caggtggcca atcacaaaat 20
 <210> 9
 <211> 22
 <212> DNA
 50
 <213> Artifical Sequence
 <220>
 <223> Description of Artifical Sequence:
 55
 Primer
 <400> 9
 ctcaaagtgg aaccatctgc ta 22
 60

5 <210> 10
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:
Primer
10 <400> 10
ggaaaccag tccatgttcc 20
15 <210> 11
<211> 21
<212> DNA
<213> Artificial Sequence
<220>
20 <223> Description of Artificial Sequence:
Primer
<400> 11
25 cctgggcctt ttcttcata g t 21
<210> 12
<211> 19
<212> DNA
30 <213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:
35 Primer
<400> 12
ctcaagctcc cctctgcct 19
40 <210> 13
<211> 19
<212> DNA
<213> Artificial Sequence
45 <220>
<223> Description of Artificial Sequence:
Primer
50 <400> 13
tcagaagcat aacctgctg 19
<210> 14
<211> 20
55 <212> DNA
<213> Artificial Sequence
<220>
60 <223> Description of Artificial Sequence:
Primer

<400> 14
ccagttcacc aatcagcagg 20

5 <210> 15
<211> 20
<212> DNA
<213> Artificial Sequence

10 <220>
<223> Description of Artificial Sequence:
Primer

15 <400> 15
cccctgctga t-ggtgaact 20

<210> 16
<211> 20
20 <212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:

25 Primer

<400> 16
tgtagggcag gtatttcagc 20

30 <210> 17
<211> 19
<212> DNA
<213> Artificial Sequence

35 <220>
<223> Description of Artificial Sequence:
Primer

40 <400> 17
agcccatcga gtacggcaa 19

<210> 18
<211> 20
45 <212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:

50 Primer

<400> 18
55 cctcagaaca aaagcccatc 20

<210> 19
<211> 18
<212> DNA
60 <213> Artificial Sequence

<220>
<223> Description of Artifical Sequence:

5 Primer

<400> 19
tcttgctcgg acctcggc 18

10 <210> 20
 <211> 20
 <212> DNA
 <213> Artifical Sequence

15 <220>
 <223> Description of Artifical Sequence:

 Primer

20 <400> 20
 gtgatccaca cgaaccagtg 20

25 <210> 21
 <211> 19
 <212> DNA
 <213> Artifical Sequence

30 <220>
 <223> Description of Artifical Sequence:

 Primer

35 <400> 21
 gaagaaccca gccaggatg 19

40 <210> 22
 <211> 20
 <212> DNA
 <213> Artifical Sequence

45 <220>
 <223> Description of Artifical:

 Primer

 <400> 22
 acagctttcc cccaattctc 20

INTERNATIONAL SEARCH REPORT

International Application No
PC/EP 00/01979

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/53 C12N15/85 C12N15/11 C12N9/02 C12Q1/02
C07K16/40 A61K39/395 A61K38/44 A01K67/027 G01N33/50
G01N33/53

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C12Q C07K A61K A01K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------|
| X | "AC A1394672" EMBL DATABASE, 5 February 1999 (1999-02-05), XP002111712 Heidelberg the whole document --- | 1-12 |
| X | WO 98 46763 A (THURMOND JENNIFER ; CALGENE LLC (US); ABBOTT LAB (US); KNUTZON DEBO) 22 October 1998 (1998-10-22) * see esp. SEQ ID NOS: 27-40 --- | 1-12, 17, 18 |
| X | CHO H P ET AL: "Cloning, expression, and nutritional regulation of the mammalian Delta-6 desaturase." JOURNAL OF BIOLOGICAL CHEMISTRY, (1999 JAN 1) 274 (1) 471-7., XP002111713 the whole document --- -/- | 1-12, 17, 18 |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

27 July 2000

Date of mailing of the international search report

16.08.00

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel: (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3018

Authorized officer

Kania, T

INTERNATIONAL SEARCH REPORT

International Application No
PC./EP 00/01979

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------|
| X | "AC 060426" EMBL DATABASE, 1 August 1998 (1998-08-01), XP002111714 Heidelberg the whole document --- | 7-10 |
| X | "AC 060427" EMBL DATABASE, 1 August 1998 (1998-08-01), XP002111715 Heidelberg the whole document --- | 7-10 |
| X | WO 98 39446 A (HUMAN GENOME SCIENCES INC) 11 September 1998 (1998-09-11) see esp. p.48 l.20 - p.49 l.7; p.78; SEQ ID NO:63,186 --- | 1-10 |
| A | OLGA SAYANOVA ET AL: "Expression of a borage desaturase cDNA containing an N-terminal cytochrome b5 domain results in the accumulation of high levels of Delta6-desaturated fatty acids in transgenic tobacco" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 94, no. 94, 15 April 1997 (1997-04-15), pages 4211-4216 4216, XP002106758 ISSN: 0027-8424 the whole document --- | 1-18 |
| A | MITCHELL, ANDREW G. ET AL: "A novel cytochrome b-5-like domain is linked to the carboxyl terminus of the Saccharomyces cerevisiae DELTA-9 fatty acid desaturase." JOURNAL OF BIOLOGICAL CHEMISTRY, (1995) VOL. 270, NO. 50, PP. 29766-29772, XP002111716 the whole document --- | 1-18 |
| A | WO 96 02561 A (GEN HOSPITAL CORP ; GENETICS INST (US)) 1 February 1996 (1996-02-01) the whole document --- | 14,16 |
| A | WO 99 04262 A (MYELOS NEUROSCIENCES CORP) 28 January 1999 (1999-01-28) * see esp. claims * --- | 15,16 |
| | --- -/-- | |

INTERNATIONAL SEARCH REPORT

International Application No
PC/EP 00/01979

| C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT | | |
|--|--|-----------------------|
| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
| P,X | CHO, HYEKYUNG P ET AL: "Cloning, expression, and fatty acid regulation of the human DELTA-5 desaturase." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 52, 24 December 1999 (1999-12-24), pages 37335-37339, XP002143650 ISSN: 0021-9258 the whole document & "AC AF199596" EBI DATABASE, 1 February 2000 (2000-02-01), the whole document --- | 1-10, 13 |
| P,X | WO 00 00622 A (INCYTE PHARMA INC ;CORLEY NEIL C (US); BANDMAN OLGA (US); BAUGHN M) 5 January 2000 (2000-01-06) see th whole document; esp. SEQ ID NO:5,11 --- | 1-13, 16-18 |
| P,X | LI W. ET AL.: "Human delta-6 fatty acid desaturase (CYB5RP); AC AF134404" EBI DATABASE, 19 May 1999 (1999-05-19), XP002143651 the whole document --- | 1-10 |
| E | WO 00 21557 A (CASKEY C THOMAS ;MERCK & CO INC (US); PETRUKHIN KONSTANTIN (US)) 20 April 2000 (2000-04-20) the whole document ----- | 1-14, 16-18 |

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 00/01979

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

 Claims 14 and 15 were only interpreted and searched with reference to the use of the present molecules and vectors in these assays.
 Claim 16 could not be searched completely due to the lack of characterization of the claimed subject

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. ☒ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims 14 and 15 were only interpreted and searched with reference to the use of the present molecules and vectors in these assays.
Claim 16 could not be searched completely due to the lack of characterization of the claimed subject matter.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: 1-18 partially

An isolated polynucleotide selected from the group consisting of polynucleotides having at least 65%, preferably 80% homology with a polynucleotide encoding a polypeptide of SEQ ID NO:4, comprising variants, under stringent conditions hybridizing molecules, complementary molecules, and oligonucleotides comprising at least 15 consecutive nucleotides of said sequence, preferably the polynucleotide of SEQ ID NO:1. Vectors, host cells, and transgenic organisms comprising said sequences.

A polypeptide comprising a sequence having at least 65%, more preferably 85% homology to SEQ ID NO:4, variants thereof, and a peptide comprising at least 15 consecutive amino acids thereof. A process for producing said polypeptide using said host cells and DNA sequences. Antibodies against said polypeptides, and their use in diagnosis and therapy.

An oligonucleotide primer having a sequence selected from the group of nucleotide sequences of SEQ ID NOs:7-12. A method of screening for modulators in known assays using constructs or of screening for interacting proteins or factors using state of the art technologies, as well as a method of screening chemical libraries comprising transformed cell lines, both methods employing the said sequences, vectors, or host cells.

A compound which alters or reacts with at least one epitope of the proteins and which is obtained by said methods. Pharmaceutical compositions comprising as an effective component an effective amount of said peptides.

2. Claims: 1-18 partially

idem for SEQ ID NOs:2,5,13-18

3. Claims: 1-18 partially

idem for SEQ ID NOs:3,6,19-22

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern. Appl. Application No

PCT/EP 00/01979

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|---|---------------------|----------------------------|---------------------|
| WO 9846763 A | 22-10-1998 | US 5968809 A | 19-10-1999 |
| | | AU 6961698 A | 11-11-1998 |
| | | AU 720677 B | 08-06-2000 |
| | | AU 7114798 A | 11-11-1998 |
| | | BG 103797 A | 28-04-2000 |
| | | CN 1252099 T | 03-05-2000 |
| | | EP 0975766 A | 02-02-2000 |
| | | EP 0996732 A | 03-05-2000 |
| | | NO 994925 A | 30-11-1999 |
| | | NO 994926 A | 30-11-1999 |
| | | WO 9846764 A | 22-10-1998 |
| WO 9839446 A | 11-09-1998 | AU 6545398 A | 22-09-1998 |
| | | EP 0972029 A | 19-01-2000 |
| | | EP 0972030 A | 19-01-2000 |
| | | WO 9839448 A | 11-09-1998 |
| WO 9602561 A | 01-02-1996 | EP 0773952 A | 21-05-1997 |
| | | JP 10504713 T | 12-05-1998 |
| | | US 6004746 A | 21-12-1999 |
| WO 9904262 A | 28-01-1999 | AU 8480798 A | 10-02-1999 |
| | | EP 0996856 A | 03-05-2000 |
| WO 0000622 A | 06-01-2000 | AU 4843799 A | 17-01-2000 |
| WO 0021557 A | 20-04-2000 | NONE | |